{"id":21277,"date":"2023-03-01T15:35:22","date_gmt":"2023-03-01T15:35:22","guid":{"rendered":"https:\/\/msdconecta.co.cr\/es\/?page_id=21277"},"modified":"2023-09-06T20:21:24","modified_gmt":"2023-09-06T20:21:24","slug":"guia-esaic-wp-0231","status":"publish","type":"page","link":"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/","title":{"rendered":"Gu\u00eda ESAIC"},"content":{"rendered":"\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2eb6e43a75720a52a91cfcc742668855 wp-block-paragraph\">Reprinted from E<small>UROPEAN<\/small>&nbsp;J<small>OURNAL OF<\/small>&nbsp;A<small>NAESTHESIOLOGY<\/small><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--687b155a092316f2ed4da39efeb56835 wp-block-paragraph\">November 16, 2022<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2540a0f5767b22f26114631e2d240338 wp-block-paragraph\">Copyright \u00a9 2022 European Society of Anaesthesiology and Intensive Care<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f9f262ab96b27b791b2b9d87f25f0103 wp-block-paragraph\">Published by Lippincott Williams &amp; Wilkins\u2003Printed in U.S.A.<\/p>\n\n\n<figure class=\"wp-block-table mhh-mcn-v1-table mhh-mcn-v1-table--e7df37ac192cfd85c957103246730f02\"><table><tbody><tr><td><img decoding=\"async\" src=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/images\/logo1.jpg\" alt=\"images\"><\/td><td><em>Eur J Anaesthesiol<\/em>\u00a02022;\u00a0<strong>39<\/strong>:1\u201313<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--align-center mhh-mcn-v1-links--justified-center mhh-mcn-v1-links--f5b61fdcaa5e15038ff71d06c8ca77fd\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--117932052b2b9191b11a5b13e0b481f1 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-custom\" href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php\" target=\"_blank\" rel=\"noopener noreferrer\">\n                    <span class=\"mhh-mcn-v1-link__label\">Click ac\u00e1 para dercargar PDF<\/span>\n                <\/a><\/div>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--63c40d1d4f1328714d4517673f7366c1 wp-block-paragraph\"><strong>GUIDELINES<\/strong><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--16a145638225ae81fa156445fb579742 wp-block-paragraph\">Peri-operative management of neuromuscular blockade<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--8f512e664f67c1a3bd463095860aaf90 wp-block-paragraph\"><em>A guideline from the European Society of Anaesthesiology and Intensive Care<\/em><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d982ac11e8bf9fa67f0192d565b7ad88 wp-block-paragraph\">Thomas Fuchs-Buder, Carolina S. Romero, Heidrun Lewald, Massimo Lamperti, Arash Afshari, Ana-Marjia Hristovska, Denis Schmartz, Jochen Hinkelbein, Dan Longrois, Maria Popp, Hans D. de Boer, Massimiliano Sorbello, Radmilo Jankovic and Peter Kranke<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--cb0e26dc2ea37b030c1b2641499cf57d wp-block-paragraph\">Recent data indicated a high incidence of inappropriate management of neuromuscular block, with a high rate of residual paralysis and relaxant-associated postoperative complications. These data are alarming in that the available neuromuscular monitoring, as well as myorelaxants and their antagonists basically allow well tolerated management of neuromuscular blockade. In this first European Society of Anaesthesiology and Intensive Care (ESAIC) guideline on peri-operative management of neuromuscular block, we aim to present aggregated and evidence-based recommendations to assist clinicians provide best medical care and ensure patient safety. We identified three main clinical questions: Are myorelaxants necessary to facilitate tracheal intubation in adults? Does the intensity of neuromuscular blockade influence a patient&#8217;s outcome in abdominal surgery? What are the strategies for the diagnosis and treatment of residual paralysis? On the basis of this, PICO (patient, intervention, comparator, outcome) questions were derived that guided a structured literature search. A stepwise approach was used to reduce the number of trials of the initial research (<em>n<\/em>&gt; = 24 000) to the finally relevant clinical studies (<em>n<\/em>&nbsp;= 88). GRADE methodology (Grading of Recommendations, Assessment, Development and Evaluation) was used for formulating the recommendations based on the findings of the included studies in conjunction with their methodological quality. A two-step Delphi process was used to determine the agreement of the panel members with the recommendations:&nbsp;<strong>R1<\/strong>&nbsp;We recommend using a muscle relaxant to facilitate tracheal intubation (1A).&nbsp;<strong>R2<\/strong>&nbsp;We recommend the use of muscle relaxants to reduce pharyngeal and\/or laryngeal injury following endotracheal intubation (1C).&nbsp;<strong>R3<\/strong>&nbsp;We recommend the use of a fast-acting muscle relaxant for rapid sequence induction intubation (RSII) such as succinylcholine 1 mg kg<sup>\u20131<\/sup>&nbsp;or rocuronium 0.9 to 1.2 mg kg<sup>\u20131<\/sup>&nbsp;(1B).&nbsp;<strong>R4<\/strong>&nbsp;We recommend deepening neuromuscular blockade if surgical conditions need to be improved (1B).&nbsp;<strong>R5<\/strong>&nbsp;There is insufficient evidence to recommend deep neuromuscular blockade in general to reduce postoperative pain or decrease the incidence of peri-operative complications. (2C).&nbsp;<strong>R6<\/strong>&nbsp;We recommend the use of ulnar nerve stimulation and quantitative neuromuscular monitoring at the adductor pollicis muscle to exclude residual paralysis (1B).&nbsp;<strong>R7<\/strong>&nbsp;We recommend using sugammadex to antagonise deep, moderate and shallow neuromuscular blockade induced by aminosteroidal agents (rocuronium, vecuronium) (1A).&nbsp;<strong>R8<\/strong>&nbsp;We recommend advanced spontaneous recovery (i.e. TOF ratio &gt;0.2) before starting neostigmine-based reversal and to continue quantitative monitoring of neuromuscular blockade until a TOF ratio of more than 0.9 has been attained. (1C)<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--795fd7ed6cb9f40eace5afaf507bc793 wp-block-paragraph\"><strong>Published online xx month 2022<\/strong><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7ba2ee321402def3a1137f72d3ec0465 wp-block-paragraph\">From the Department of Anaesthesiology, Intensive Care and Peri-operative Medicine, CHRU de Nancy, Nancy, France (TF-B), Department of Anesthesia and Critical Care, Consorcio Hospital General Universitario de Valencia, Methodology Department, Universidad Europea de Valencia, Valencia, Spain (C-S.R), Department of Anesthesiology and Intensive Care, Technical University of Munich, Munich, Germany (HL), Anesthesiology Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (ML), Department of Paediatric and Obstetric Anaesthesia, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (AA), Department of Anaesthesiology &amp; Intensive Care Medicine, Copenhagen University Hospital, Hvidovre, Denmark (A-MH), Department of Anesthesiology, CUB H\u00f4pital Erasme, Bruxelles, Belgium (DS), Department of Anaesthesiology and Intensive Care Medicine, University Hospital of Cologne, Cologne, Germany (JH), Department of Anesthesia and Intensive Care, H\u00f4pital Bichat-Claude Bernard, Universit\u00e9 de Paris, Paris, France (DL), Department of Anaesthesia, Critical Care Medicine, Emergency Medicine and Pain Medicine, University Hospitals of Wuerzburg, Wuerzburg, Germany (MP, PK), Department of Anesthesiology Pain Medicine &amp; Procedural Sedation and Analgesia Martini General Hospital Groningen, Groningen, The Netherlands (HDDB), Anesthesia and Intensive Care, AOU Policlinico &#8211; San Marco, Catania, Italy (MS), Clinic for Anesthesiology and Intensive Therapy, University Clinical Center Nis, School of Medicine, University of Nis, Nis, Serbia (RJ)<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--43a0f081b2b000d7ac30ef561c1bf368 wp-block-paragraph\">Correspondence to Thomas Fuchs-Buder, MD, Department of Anesthesiology, Critical Care and Peri-operative Medecine, CHRU Nancy\/H\u00f4pital de Brabois, Nancy-Les-Vandoeuvre France<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2c2c8814dabc09e247b3c71b34888248 wp-block-paragraph\">Tel: +33 383 153942; e-mail:&nbsp;<a href=\"mailto:t.fuchs-buder@chru-nancy.fr\">t.fuchs-buder@chru-nancy.fr<\/a><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2f998d1979c36ab8e491273362a48de6 wp-block-paragraph\">0265-0215 Copyright \u00a9 2022 European Society of Anaesthesiology and Intensive Care. Unauthorized reproduction of this article is prohibited.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--6f2d5d13b62f3ff33088dcff643b9fce wp-block-paragraph\">DOI:<a href=\"http:\/\/doi.org\/10.1097\/EJA.0000000000001769\">10.1097\/EJA.0000000000001769<\/a><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--26a7aff89adfbcaf155fcccade02a7d5 wp-block-paragraph\">Introduction<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--3124feff656ac179237334e449a56638 wp-block-paragraph\">A recent survey addressed the practice of neuromuscular block management in Europe. In this survey, 17 150 patients were exposed to a neuromuscular blocking agent, but neuromuscular monitoring (NMM) was not used in more than 10 000 of them, timing of extubation was solely based on clinical criteria in around 12 000 patients, and over 8300 patients did not receive any reversal agent at the end of surgery. Finally, only 16.5% of patients (2839\/17 150) exposed to a neuromuscular blocking agent were extubated with a documented train-of-four (TOF)-ratio at least 0.9.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref1\">1<\/a><\/sup>&nbsp;Unsurprisingly, this very high incidence of inappropriate management of neuromuscular block increased the rate of residual paralysis and relaxant-associated postoperative pulmonary complications (POPCs).<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref1\">1<\/a><\/sup><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--761c6f9446df36414154529f0c117ce0 wp-block-paragraph\">So far, the peri-operative management of neuromuscular blockade has not yet been addressed by a guideline from the European Society of Anaesthesiology and Intensive Care (ESAIC). Hence, in light of the above-mentioned distressing snapshot of the practice of neuromuscular blockade management across Europe and with the intention of improving patient safety, a task force was assigned by the ESAIC to critically appraise the current literature in the field and to provide a graded and evidence-based set of practice guidelines for the peri-operative management of neuromuscular blockade.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ddbb0f71fae4bcdeca441c844e1bc709 wp-block-paragraph\">Materials and methods<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1e301b09dc50d917eb9c1ad62a84178a wp-block-paragraph\">The ESAIC appointed a task force to develop guidelines on the peri-operative management of neuromuscular blockade. Clinical queries were developed in the form of three Population\/Intervention\/Comparison\/Outcome (PICO) groups and then further into eight elements for the search strategy. The initial list of PICOs was then revised and finally a consolidated set of PICOs was approved by the task force. PICOs generated were based on the research questions to be addressed in this article. The main clinical queries arising from the shortcomings in conjunction with the use of neuromuscular blocking agents and its monitoring and reversal that was explained in the Introduction were as follows:<\/p>\n\n\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--65bef7d8f0422632b7aaf6a1468d6243 wp-block-paragraph\">Criteria for considering studies for data analysis<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ad661ac90d8115e1f310bd43ed0620ff wp-block-paragraph\">Types of studies<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d4688cc13e6abd12d15de1c1f08ce550 wp-block-paragraph\">Data analysis included all randomised, parallel and quasi-randomised studies (including crossover studies) and observational studies performed in adults that addressed any of the above queries. Previous meta-analyses and systematic reviews were considered when available and meeting the inclusion criteria. Data from quasi-randomised and observational and large retrospective studies were included to support the answer to the PICOs due to the small number of randomised controlled trials (RCTs) available. Narrative reviews, case series and case reports as well as published abstracts from conference proceedings and registered but not completed studies were excluded.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--41e0c459256f82699307ab05c9c1a902 wp-block-paragraph\">Types of participants<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--03de6be91531c0b1426795c4499112d7 wp-block-paragraph\">The qualitative and quantitative analysis of the literature was confined to adult patients undergoing surgery with general anaesthesia and tracheal intubation.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--4a3634ed74e445726d6abe9649a822a7 wp-block-paragraph\">Type of interventions<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7edeabb34a035af2d158e41cef08e420 wp-block-paragraph\">We included the following interventions: neuromuscular blockade (type of neuromuscular blocking agent: suxamethonium, atracurium, cisatracurium, mivacurium, pancuronium, rapacuronium, vecuronium and rocuronium), quantitative NMM or acceleromyography or electromyography, sugammadex-based reversal.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1c5a5ed1a2326b9ec066d3c7b9545133 wp-block-paragraph\">Types of comparators<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--57905196744dbe1e09bc1bf7a4998522 wp-block-paragraph\">We included the following comparators: no or any different degree of neuromuscular blockade, no NMM or qualitative NMM [i.e. peripheral nerve stimulator (PNS)], neostigmine-based reversal.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--cdf56e31866a7145f68672c26da574af wp-block-paragraph\">Types of outcomes<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c82583242d59c33508177e5e545678ae wp-block-paragraph\">Outcomes included assessment of intubation conditions, either by the criteria of Cormack and Lehane or those of the &#8216;Good Clinical Research Practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents&#8217;, sore throat, hoarseness, vocal cord injury, pharyngeal injury, dental injury, oesophageal intubation, inhalation lung disease, surgical field quality score, laparoscopic insufflation pressure, postoperative pain in the PACU, postoperative pain at 24 h postsurgery, intra-operative adverse events, postoperative complications within 30 days using the Clavien-Dindo classification, residual paralysis, TOF ratio less than 0.9, hypoxia, and POPC.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1c27960638f17f2796d9d128098df21b wp-block-paragraph\">Search method for identification of studies<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d5dd2dc05ec6c4b2269c9fefb719c922 wp-block-paragraph\">The literature search strategy was developed by the trial search and Cochrane information specialist Janne Vendt (Copenhagen University Hospital, Copenhagen, Denmark) in close collaboration with the author T.F-B. and the ESAIC group methodologist and Cochrane editor A.A. We searched for eligible studies in the following databases: Medline (Ovid SP, 1946 \u2013 search date), Embase (Ovid SP, 1974 \u2013 search date), Central (Cochrane Database of Systematic Reviews &lt;<a href=\"https:\/\/www.cochranelibrary.com\/\">https:\/\/www.cochranelibrary.com\/<\/a>&gt;Issue 1 of 12 January 2021), Web of Science (1900 \u2013 search date), Biosis (1969 \u2013 search date). A combination of subject headings and free-text terms was used for the topic search. We added filters for study types inspired by NICE (i.e. National Institute for Health and Care Excellence), but adjusted for our use. (<a href=\"https:\/\/www.nice.org.uk\/process\/pmg20\/chapter\/identifying-the-evidence-literature-searching-and-evidence-submission#developing-search-strategies\">https:\/\/www.nice.org.uk\/process\/pmg20\/chapter\/identifying-the-evidence-literature-searching-and-evidence-submission#developing-search-strategies<\/a>). An additional search for systematic reviews was run in Epistemonikos, and the bibliographic references and citations of included studies and systematic reviews were checked for other eligible studies. During the screening process, the search was limited to 1995 to 2021 and only references published in this period were screened. The task force members were also encouraged to add any missing articles of interest of which they were aware and to conduct additional searches themselves. The titles resulting from the searches were allocated to the three PICO groups and screened by respective task force members as follows: PICO 1: C-S.R, H.L., M.S., PICO 2: P.K., M.P., J.H., D.S., PICO 3: M.L., HDD.B., A-M.H, T.F-B.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2c1c4bf8a06bdfaf9f05534fced2b7d9 wp-block-paragraph\">The searches for the guideline were run on 1 February 2021 and updated on 31 December 2021.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d874b311147f601036d12ec312b6c553 wp-block-paragraph\">Search results<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--50b333e543c4a112889fa2ac2927a17d wp-block-paragraph\">Three of the authors first screened the titles and then relevant titles with abstracts in a two-stage procedure. In the first stage, a &#8216;second opinion&#8217; was possible, later to be reviewed by T.F-B. The screening procedure was monitored by either A.A or P.K. The resulting potentially relevant articles were retrieved for full-text assessment and data extraction by the task force groups using Rayyan software (<a href=\"https:\/\/www.rayyan.ai\/\">https:\/\/www.rayyan.ai<\/a>).<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7fa40bb8e2385b287fb156ef39394022 wp-block-paragraph\">During the initial research, 24 000 titles could be identified; after duplicate removal and limitation of the search period to 1996 to 2021, the remaining 13 115 titles were screened, resulting in 1988 abstracts. From these, 166 relevant abstracts were used to select a total of 88 appropriate titles for a detailed GRADE (Grading of Recommendations, Assessment, Development and Evaluation) analysis. Moreover, three systematic reviews and one meta-analysis were considered. For a more detailed description of the search strategy and PICO queries, the readers are referred to Appendix 1.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--54942e2b1aae1fcca437841086d01922 wp-block-paragraph\">Data collection and analysis<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b82a60507d9108361155e7033b007b4c wp-block-paragraph\">Selection of studies<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--0acf053051f2e61f2d7e966729dc7636 wp-block-paragraph\">All articles meeting the inclusion criteria were included. At least two authors within each of the three PICO groups assessed the relevant full-text articles (PICO 1: H.L., C-S.R; PICO2: P.K., M.P., J.H., D.S.; PICO3: M.L., HDDB, T.F-B.). Disagreements were resolved by a third party (A.A, P.K., T.F-B.)<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b31f72bb3609e365c32b77b67f71e20c wp-block-paragraph\">Data extraction and management<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ab7accead5862827ce1a9b390f58c8e0 wp-block-paragraph\">All authors extracted data in a similar manner in relation to study design, patient characteristics, intervention and outcome measures. The respective data were entered in a predesigned Excel sheet. Task force group authors reached consensus regarding extracted data through discussion.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--4a0ff5ee2b419bb93e37e901410170e4 wp-block-paragraph\">Assessment of risk of bias in included studies<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--bb377b65dce6415553700459356d2644 wp-block-paragraph\">Review authors were supplied with literature for assessment of risk of bias by the ESAIC methodologist (A.A.), and then assessed the risk of bias of each of the studies selected for each PICO question. Risk of bias assessment was conducted in accordance with the Cochrane Handbook for Systematic Reviews and Interventions. The risk of bias was assessed for the following domains:<\/p>\n\n\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--e5236658906e11703c250deb60d6c00b wp-block-paragraph\">Overall bias was defined by the assessor based on the assessment in the respective domains. Basically, trials were assessed as having a low risk of bias if all of the domains were considered adequate, as having a moderate risk of bias if one domain was considered inadequate, and as having a high risk of bias if more than one domain were considered inadequate or unclear. Disagreement regarding assessment of risk of bias was settled in discussion with the methodologist (A.A.).<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--99730c7826d79196315ae34f4a4be8aa wp-block-paragraph\">Assessment of quality of the evidence<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--4640a4d71bd076782f855cbac7533df7 wp-block-paragraph\">In accordance with the ESAIC policy, GRADE methodology was used for formulating the recommendations based on the findings of the included studies in conjunction with their methodological quality. The ESAIC guidelines committee selected the GRADE system for assessing levels of evidence and grading as this method has the merit of simplicity. Two levels also make the interpretation of the implications of strong and weak recommendations simpler for clinicians. The Taskforce members were asked to define relevant outcomes across all clusters and rank the relative importance of outcomes, following a process proposed by the GRADE group. After selecting the relevant articles for each cluster, one member per group was in charge for the final grading of the papers (C-S.R, P.K, T.F-B). Decisions to downgrade the level of evidence for a recommendation were based on the quality and type of the included literature, observed inconsistencies, indirectness or directness of the evidence, overall impression of the quality of the evidence and the presence of publication bias as indicated by GRADE. Decisions to upgrade the level of evidence for recommendations were based on study quality and magnitude of effect, dose-response gradient and plausible residual confounding. The GRADE definitions are summarised in&nbsp;<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#tab1\">Table 1<\/a>.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--e2cf4cf4a2260df229b000bea6c34baf wp-block-paragraph\" id=\"tab1\">Table 1&nbsp;GRADE definitions<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/images\/tab1.jpg\" alt=\"images\" \/><\/figure>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d88e824d23b0d0bd9773b9f9e681b8b8 wp-block-paragraph\">Development of recommendations<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a22a42eea983a7a4107596936600137c wp-block-paragraph\">Each group developed recommendations relevant to their PICO and clinical questions. These were then discussed and re-discussed as required with the entire expert panel in light of the data synthesis, the risk of bias and the quality of the evidence.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--5605454f38bf0d5056b31f0b7b9aaa70 wp-block-paragraph\">A two-step Delphi process was used to produce expert recommendations and to discuss the methodological quality of the supporting literature when the quality of evidence was low or when rephrasing of recommendations was needed. Every single recommendation, suggestion or statement was subject to the voting and consensus process.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b15967fccab91e79193b09073d2ded06 wp-block-paragraph\">First round<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--69a03027c1a07c4e3e593629a72772ef wp-block-paragraph\">At the first round, the statements of task force groups were discussed and refined at a hybrid meeting (face-to-face at EuroAnaesthesia 2022 in Milan and videoconferencing for task force members not present). A set of eight statements was identified for further development.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--3795509cefc834aa62c55d639b896351 wp-block-paragraph\">Second round<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9062a8e0a2d44f7574ce27dd4e59aa80 wp-block-paragraph\">For the second and final round, a virtual meeting was used to ask the task force members to indicate approval or rejection of each of the eight statements, with the option for suggesting changes. An affirmative (positive) rating was adopted when the approval rate was 80%. Finally, all eight recommendations reached full agreement (10 supporting votes out of 10 participating members being eligible to vote).<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--969e9bea390ce7f994f8774131a596ca wp-block-paragraph\">In addition, recommendations for good practice (based on the experiences of the guideline task force and possibly incorporating the expertise of a wider reference group) were developed in addition to recommendations for the PICO questions based on the existent evidence. The guideline task force produced these clinical practice statements (CPS) on important topics rather than solely on evidence based recommendations when there was a lack of research evidence no predefined PICO and the conviction that the CPS added important opinions to the overall guideline topic.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--46e8a7df5764fef9cd3398e43821df70 wp-block-paragraph\">The recommendations and CPS were merged into a shared document by one author (T.F-B.). The final version of the document was composed by the authors and subsequently reviewed and endorsed by all members of the expert panel.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c45a597a27b352254b83482bf9ecc8a7 wp-block-paragraph\">Summary of recommendations (R)<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--eb2c81512dcd9ad4eead8a511d972aac wp-block-paragraph\"><strong>R1:<\/strong>&nbsp;We recommend using a muscle relaxant to facilitate tracheal intubation (1A: high quality of evidence, strong recommendation).<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d08ffb21989350850f7eb72eb935139f wp-block-paragraph\"><strong>R2:<\/strong>&nbsp;We recommend the use of muscle relaxants to reduce pharyngeal and\/or laryngeal injury following endotracheal intubation (1C: low quality of evidence, strong recommendation).<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--56cb1bf64ebae286ab6763c765435d86 wp-block-paragraph\"><strong>R3:<\/strong>&nbsp;We recommend the use of a fast-acting muscle relaxant for RSII such as succinylcholine 1 mg kg<sup>\u20131<\/sup>&nbsp;or rocuronium 0.9 to 1.2 mg kg<sup>\u20131<\/sup>&nbsp;(1B: moderate quality of evidence, strong recommendation).<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--02e447323345c62962d105c053b9b1be wp-block-paragraph\"><strong>R4:<\/strong>&nbsp;We recommend deepening neuromuscular blockade if surgical conditions need to be improved (1B: moderate quality evidence, strong recommendation).<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--111b66000c5d190892fabe2b3b8d46e2 wp-block-paragraph\"><strong>R5:<\/strong>&nbsp;There is insufficient evidence to recommend deep neuromuscular blockade in general to reduce postoperative pain or decrease the incidence of peri-operative complications. (2C: low-quality evidence, weak recommendation)<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d2f1e4963a244dd1e517c8b433609de2 wp-block-paragraph\"><strong>R6:<\/strong>&nbsp;We recommend the use of ulnar nerve stimulation and quantitative NMM at the adductor pollicis muscle to exclude residual paralysis. (1B: moderate-quality evidence, strong recommendation)<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--54854da6eb5eb853ed86fe5d9bf55d64 wp-block-paragraph\"><strong>R7:<\/strong>&nbsp;We recommend using sugammadex to antagonise deep, moderate and shallow neuromuscular blockade induced by aminosteroidal agents (rocuronium, vecuronium) (deep: posttetanic count &gt;1 and TOF count 0, moderate: TOF-count 1 to 3, shallow: TOF-count 4 and TOF-ratio &lt; 0.4) (1A: high-quality evidence, strong recommendation)<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2399542c7dbe8cecfbb545c3dab0c041 wp-block-paragraph\"><strong>R8:<\/strong>&nbsp;We recommend advanced spontaneous recovery (i.e. TOF-ratio &gt;0.2) before starting neostigmine-based reversal and to continue quantitative monitoring of neuromuscular blockade until a TOF-ratio of more than 0.9 has been attained. (1C: low-quality evidence, strong recommendation)<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--dcbca4edec42ff96973c23645ad6e934 wp-block-paragraph\">Summary of clinical practice statements<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--8b2f2091f6b5d97a0947d37235719a55 wp-block-paragraph\"><strong>CPS1:<\/strong>&nbsp;Current evidence does not allow the recommendation of one reversal agent over another when reversing a TOF-ratio between 0.4 and 0.9. The choice between sugammadex and neostigmine must consider patient-related factors as well as availability.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--13d5707ec1c2c4db7e2f253a5713ed47 wp-block-paragraph\"><strong>CPS2:<\/strong>&nbsp;Recovery from succinylcholine-induced neuromuscular blockade should also be monitored quantitatively.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--70acccf64049377f28dad0461b26682d wp-block-paragraph\">Is the use of muscle relaxants necessary to facilitate tracheal intubation?<\/p>\n\n\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--841b0eefefdaa7c4e40de4df254ca410 wp-block-paragraph\">Evidence summary and comment<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--db5fcafa64b1dc9cb26c84cefdc840e3 wp-block-paragraph\">In the assessment of the need for muscle relaxants for orotracheal intubation, 39 randomised clinical trials,<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref2\">2<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref40\">40<\/a><\/sup>&nbsp;one cohort study,<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref41\">41<\/a><\/sup>&nbsp;two systematic reviews,<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref42\">42<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref43\">43<\/a><\/sup>&nbsp;and one clinical guideline<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref44\">44<\/a><\/sup>&nbsp;were included. We considered studies that investigated succinylcholine, rocuronium, atracurium, cisatracurium, rapacuronium, mivacurium and vecuronium in the adult population. Whenever a study looked at different doses of neuromuscular blocking agents, the dose that doubled the ED<sub>95<\/sub>&nbsp;(effective dose of muscle relaxant that induces a 95% blockade) was chosen. In studies characterising different protocols without muscle relaxant, only the one protocol leading to the best intubating conditions was considered. Thus, we obtained data from 1405 patients who received a muscle relaxant for endotracheal intubation and from 1364 patients who did not receive a muscle relaxant. Poor intubation conditions were observed in 370 patients without muscle relaxant and in 45 patients who received muscle relaxants (<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#tab2\">Table 2<\/a>). These results correspond to poor intubation conditions in 27% in the group without muscle relaxants vs. 3% in the group wherein muscle relaxants were administered. From the data reported, the presence of poor intubation conditions resulted in an absolute risk reduction of 24% when using muscle relaxant drugs for intubation. These findings are further supported by Lundstrom&nbsp;<em>et al.<\/em><sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref41\">41<\/a><\/sup>&nbsp;identifying relaxant-free induction as an independent risk factor for difficult tracheal intubation.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--650977cd131f75a1caaabbb5868afae0 wp-block-paragraph\" id=\"tab2\">Table 2&nbsp;Randomised controlled trials to facilitate tracheal intubation and reduce pharyngeal discomfort<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/images\/tab2.jpg\" alt=\"images\" \/><\/figure>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1e8302e0cc1e2e70a2d2274d18457c07 wp-block-paragraph\">Orotracheal intubation is not free of risks and discomfort for patients. Most commonly observed side effects are postextubation pain, hoarseness and transient voice changes, and vocal cord injury. Seven studies have described the occurrence of pharyngeal and\/or laryngeal injury.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref6\">6<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref8\">8<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref10\">10<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref11\">11<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref24\">24<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref25\">25<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref33\">33<\/a><\/sup>&nbsp;To address the occurrence of these injuries, we pooled the total number of intubated patients with the use of muscle relaxants and the total number of patients in whom the technique was carried out without the addition of muscle relaxants. From a total of 447 patients intubated with a relaxant-free induction regimen, 173 (38%) experienced pharyngeal or laryngeal injury. However, when neuromuscular relaxants were used on a total of 397 patients, only 109 (27%) experienced pharyngeal or laryngeal injury (<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#tab2\">Table 2<\/a>). In light of these findings, the use of myorelaxants presents an absolute risk reduction of 11% in the occurrence of airway injury in patients during general anaesthesia. It has to be emphasised that pharyngeal or laryngeal injury may occur during extubation as well.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref25\">25<\/a><\/sup>&nbsp;Thus, further reduction of their incidence could be obtained by avoidance of cuffing and bucking during extubation.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--15faf2b113c6595b0d818145c1994088 wp-block-paragraph\">Patients may require a rapid sequence induction intubation (RSII) to protect against regurgitation of gastric content and pulmonary aspiration. Thus, to avoid mask ventilation, to improve intubation conditions and to reduce the risk of a difficult intubation in this situation, neuromuscular blocking agents given for a RSII should be rapid in onset. Traditionally, succinylcholine has been the most commonly used muscle relaxant for this purpose because of its fast onset and short duration; unfortunately, it can present serious side effects. Rocuronium has been suggested as an alternative to succinylcholine. According to a recent Cochrane Review, a regime with rocuronium at 0.6 to 0.7 mg kg<sup>\u20131<\/sup>&nbsp;produces less frequent excellent intubation conditions for RSII than succinylcholine.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref43\">43<\/a><\/sup>&nbsp;There were no statistical differences for either excellent or acceptable intubation conditions when the dose of rocuronium was increased at 0.9 to 1.0 or 1.2 mg kg<sup>\u20131<\/sup>.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref43\">43<\/a><\/sup>&nbsp;To overcome the longer muscular block duration of rocuronium compared with succinylcholine, an appropriate dose of sugammadex should be available in the operating room when using rocuronium for RSII.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref40\">40<\/a><\/sup><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c274548fed128e39bdaf8fc7d2dce2c1 wp-block-paragraph\">Does the intensity of neuromuscular blockade influence patient outcomes in abdominal surgery (i.e. laparotomy or laparoscopy)?<\/p>\n\n\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--841b0eefefdaa7c4e40de4df254ca410 wp-block-paragraph\">Evidence summary and comment<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--5eba08a5ed272a9e08472ca4a645c031 wp-block-paragraph\">In evaluating the need for muscle relaxants for optimal surgical conditions, 26 randomised clinical trials were included.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref45\">45<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref70\">70<\/a><\/sup>&nbsp;We considered studies that investigated deep (dNMB) vs. moderate (mNMB) or no neuromuscular block in the adult population. Across studies, dNMB was defined as a posttetanic count of 0 to 5 and mNMB as at least 1 response to TOF monitoring.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d18d673ae686afe4ec3568ca6643f923 wp-block-paragraph\">With very few exceptions,<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref56\">56<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref63\">63<\/a><\/sup>&nbsp;the used surgical technique was a laparoscopic procedure; patients were managed with either volatile or total intravenous anaesthesia. Twenty-three studies compared dNMB with mNMB as the standard of care,<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref45\">45<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref55\">55<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref57\">57<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref60\">60<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref62\">62<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref66\">66<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref68\">68<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref69\">69<\/a><\/sup>&nbsp;three studies used no neuromuscular block as control<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref56\">56<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref61\">61<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref67\">67<\/a><\/sup>&nbsp;and one study performed on-demand relaxation control.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref70\">70<\/a><\/sup>&nbsp;In our analysis, 23 out of 26 studies were classified as having a low risk of bias. However, some shortcomings must be considered: even though the majority of included studies reported some benefit from dNMB for the surgical condition, patient comfort and\/or patient safety, those results were from small studies (mostly \u226460 patients) and differences in the outcomes were marginal regarding clinical relevance. To conclude, we assess the quality of the evidence on this topic as moderate (Supplementary Table 1,&nbsp;<a href=\"http:\/\/links.lww.com\/EJA\/A781\">http:\/\/links.lww.com\/EJA\/A781<\/a>).<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--15d9d2e114580c1b192896c538edd715 wp-block-paragraph\">Overall, the studies included 1814 patients with 925 who were treated with dNMB during surgery and 889 patients who received mNMB or in three cases no relaxation. Surgical conditions and view of the surgical field were rated significantly better under dNMB in 17 studies.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref46\">46<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref48\">48<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref53\">53<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref55\">55<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref61\">61<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref63\">63<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref66\">66<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref69\">69<\/a><\/sup>&nbsp;However, the clinical benefits of this deep block concept still remain controversial. Surgical space conditions are not solely determined by the depth of neuromuscular block but also by nonrelaxation related factors such as depth or type of anaesthesia (volatile vs. intravenous). Moreover, patient-related factors such as abdominal wall constitution, adhesions, organ size, age or sex may also have an impact in this context. Finally, the requirements for neuromuscular block may not be constant during a procedure; at some stages, more relaxation might be needed than at others. Recently, it has been evaluated whether switching from moderate to deep neuromuscular block improves surgical conditions for laparoscopic surgery in the obese.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref52\">52<\/a><\/sup>&nbsp;To better control nonrelaxation-related factors, each patient was taken as their own control and surgical conditions were evaluated twice within a few minutes at a predefined stage of the procedure (at the begin of the gastro-gastro-jejunal suture). In this setting, the surgical conditions during moderate neuromuscular blockade were already good to excellent in the 55 out of 85 patients. In addition, switching from moderate to deep block, here defined as a PTC (posttetanic count) 1 to 3, improved surgical conditions in 85% of patients whilst maintaining moderate neuromuscular block led to an improvement in only 12% of investigated patients.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref52\">52<\/a><\/sup>&nbsp;These data are in favour of a personalised approach, that is rather than routinely applying a deep block, neuromuscular block should be deepened on demand if required to improve surgical conditions. A plausible mechanistic explanation that deeper neuromuscular block may enhance the surgical conditions or at least the view of the surgical field, for example open\/laparoscopic abdominal or pelvic or retroperitoneal procedures should be present.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--bd7b48ea4ab261469b7056e5add7b812 wp-block-paragraph\">In only three of the 15 studies that measured postoperative pain did the authors report significant differences between the groups, with patients benefitting from dNMB.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref49\">49<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref55\">55<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref62\">62<\/a><\/sup>&nbsp;Similarly, three out of 19 studies that looked for the occurrence of adverse events or complications in a broader sense reported overall fewer events in the dNMB group.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref48\">48<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref49\">49<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref63\">63<\/a><\/sup>&nbsp;Unfortunately, some of these patients had no neuromuscular blockade or a spontaneous neuromuscular recovery was allowed rather than maintaining a moderate neuromuscular block. Thus, more well designed studies investigating whether a deep neuromuscular block is superior to moderate neuromuscular block vis-a-vis peri-operative patient outcome are needed.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a21cafd2d393f52c2e4603f8013a1019 wp-block-paragraph\">What are the strategies for the diagnosis and treatment of residual neuromuscular paralysis?<\/p>\n\n\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--841b0eefefdaa7c4e40de4df254ca410 wp-block-paragraph\">Evidence summary and comment<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f5f664e936369dbfb39a3bf09d4ba7f3 wp-block-paragraph\">In evaluating strategies for the diagnosis of residual paralysis, studies comparing quantitative NMM vs. qualitative NMM or clinical assessment were examined; a TOF ratio less than 0.9 was considered as residual paralysis. Overall, five RCTs and one retrospective observational study, including altogether 788 patients, were analysed.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref71\">71<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref76\">76<\/a><\/sup>&nbsp;Three hundred and thirty-four patients were monitored with quantitative NMM at the adductor pollicis and 19 patients (6%) had residual paralysis. The 454 remaining patients were either monitored with qualitative NMM at the adductor pollicis or with clinical judgement and 121 of them (27%) had residual paralysis: 29 out of 164 (18%) monitored with qualitative NMM and 92 out of 290 (32%) managed without NMM (<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#tab3\">Table 3<\/a>). In addition, a meta-analysis, including 12 664 patients, was considered.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref77\">77<\/a><\/sup>&nbsp;It revealed a pooled incidence of residual paralysis associated with the use of a quantitative NMM of 0.115 (95% CI: 0.057 to 0.188). This was significantly lower than with qualitative NMM (0.306, 95% CI: 0.09 to 0.411) or without NMM (0.331, 95% CI: 0.234 to 0.435); qualitative NMM was not significantly different from no NMM. Compared with continuous monitoring, the isolated application of quantitative NMM at the end of surgery is less reliable to detect residual paralysis.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref78\">78<\/a><\/sup>&nbsp;Hence, quantitative NMM should be performed continuously, starting before administration of the neuromuscular blocking agent and, depending of the respective device, calibration, determination of a reference value or identification of supramaximal stimulation may be required. A TOF ratio at least 0.9 is the minimum neuromuscular recovery required before extubation; however, when raw (uncalibrated and nonnormalised) AMG (acceleromyographic) TOF ratios are used, the threshold should be 1.0.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref79\">79<\/a><\/sup><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1db9a4eed5bdbe3eb99891c9cd9b062d wp-block-paragraph\" id=\"tab3\">Table 3&nbsp;Residual paralysis: quantitative neuromuscular monitoring vs. qualitative neuromuscular monitoring or clinical signs<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/images\/tab3.jpg\" alt=\"images\" \/><\/figure>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a379e8e8568978a1c5f528a16b4cc15c wp-block-paragraph\">The results emerge from small studies (mostly around 100 patients) and two of them considered a TOF ratio of 0.7 and 0.8 as the threshold to exclude residual paralysis.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref71\">71<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref72\">72<\/a><\/sup>&nbsp;Summarised, we assess the quality of the evidence on this topic as moderate. There is convincing evidence that quantitative NMM compared with qualitative NMM or clinical judgement reduces the risk of residual paralysis consistently and substantially.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c5040289e77e6b4e2dd9ebccd3c54542 wp-block-paragraph\">To evaluate strategies for the treatment of residual paralysis, studies exploring neuromuscular recovery and POPCs after sugammadex-based and neostigmine-based reversal were examined; a TOF ratio less than 0.9 was considered as residual paralysis.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--81c429a319b1a34d7dff1bf976fb815c wp-block-paragraph\">A Cochrane systematic review reported shorter times to a TOF ratio of at least 0.9 when the NMB in patients with moderate or deep neuromuscular block were antagonised with sugammadex compared with neostigmine (moderate: 2 vs. 12.9 min; deep: 2.9 vs. 48.8 min).<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref80\">80<\/a><\/sup>&nbsp;Four RCTs reported shorter times to a TOF ratio of 0.9 when shallow or minimal (TOF ratio 0.4 to 0.9) neuromuscular blocks were antagonised with sugammadex compared with neostigmine, and all sugammadex patients recovered to a TOF ratio of at least 0.9 within 5 min.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref81\">81<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref84\">84<\/a><\/sup>&nbsp;This threshold was not attained by all patients within 10, 15 or 30 min after neostigmine 40 to 50 \u00b5g kg<sup>\u20131<\/sup>&nbsp;given at a TOF ratio of 0.2&nbsp;<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref79\">79<\/a><\/sup>&nbsp;and 0.1.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref82\">82<\/a><\/sup>&nbsp;Given a TOF ratio of 0.5, all neostigmine patients recovered to a TOF ratio of at least 0.9 within 5 min.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref84\">84<\/a><\/sup><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1d4239c3f4b839110c84411bf42ae643 wp-block-paragraph\">Nine RCTs and one retrospective observational study investigated the incidence of residual paralysis after sugammadex-based compared with neostigmine-based reversal (<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#tab4\">Table 4<\/a>).<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref76\">76<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref83\">83<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref85\">85<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref92\">92<\/a><\/sup>&nbsp;It was 2% (14\/637 patients) with sugammadex 2 to 4 mg kg<sup>\u20131<\/sup>&nbsp;and increased to 24% (141\/584 patients) with neostigmine (30 to 50 \u00b5g kg<sup>\u20131<\/sup>), corresponding to an absolute risk reduction of 22%. One prospective observational study and one RCT that investigated the incidence of POPCs after reversal with either neostigmine or sugammadex were considered.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref89\">89<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref92\">92<\/a><\/sup>&nbsp;The first study reported a significant reduction of POPC with sugammadex compared with neostigmine; the second RCT, although underpowered, could not confirm these findings. However, given the multifactorial causes of POPC, large observational studies may be more appropriate to answer this question.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref93\">93<\/a><\/sup>&nbsp;A multicentre matched cohort analysis with 2 x 22 856 patients observed a lower incidence of pulmonary complications (3.5 vs. 4.8%), pneumonia (1.3 vs. 2.2%) and respiratory failure (0.8 vs. 1.7%) after sugammadex compared with neostigmine.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref94\">94<\/a><\/sup>&nbsp;Similar results were reported in a cohort comprising 7316 patients, in whom the change from neostigmine, as a standard pharmacologic reversal agent, to sugammadex was associated with a reduction of POPC from 6.1 to 4.2%.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref95\">95<\/a><\/sup><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--faa5b097b72cf0faed4330578279fd67 wp-block-paragraph\" id=\"tab4\">Table 4&nbsp;Residual paralysis: neostigmine vs. sugammadex<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/images\/tab4.jpg\" alt=\"images\" \/><\/figure>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ec296ffd92bbb321fd4a6ff422f171e8 wp-block-paragraph\">There is convincing evidence that residual paralysis and POPC are more frequent after neostigmine-based reversal compared with sugammadex-based reversal, and the better is the neuromuscular recovery, the better is the pulmonary outcome.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref96\">96<\/a><\/sup>&nbsp;However, the use of sugammadex is limited to vecuronium or rocuronium-induced neuromuscular blockade, a prerequisite that is not always fulfilled.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref1\">1<\/a><\/sup>&nbsp;To increase the likelihood of effective reversal, the conditions that determined the action of neostigmine should be optimised. Ten minutes after 40 \u00b5g kg<sup>\u20131<\/sup>&nbsp;neostigmine was administered at the return of the fourth response of the TOF, 35% of patients still had a TOF ratio less than 0.9; this confirms that effective reversal is not guaranteed with a TOF count of 4 if the fourth response is still very weak.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref97\">97<\/a><\/sup>&nbsp;Moreover, increasing the dose will not improve this result, as higher doses have not been reported as more effective. Reversal time and prereversal recovery are the only remaining variables to improve the action of neostigmine; the less the prereversal recovery, the more the time required to attain a TOF ratio of at least 0.9,<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref98\">98<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref100\">100<\/a><\/sup>&nbsp;<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#tab5\">Table 5<\/a>. Baurain&nbsp;<em>et al.<\/em><sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref98\">98<\/a><\/sup>&nbsp;observed the best recovery of the TOF ratio 15 min after 40 \u00b5g kg<sup>\u20131<\/sup>&nbsp;neostigmine given at a prereversal twitch height of 25 to 50%. However, reversal times considerably longer than 30 min must be expected in some patients when neostigmine is given at lower degrees of spontaneous recovery. Thus, if reversal with neostigmine (40 \u00b5g kg<sup>\u20131<\/sup>) is desired within 10 to 15 min of administration, we recommend advanced spontaneous recovery (i.e. TOF ratio &gt;0.2) at the time of neostigmine administration. However, accepting a longer interval (i.e. 15 to 30 min) between administration of neostigmine and adequate neuromuscular recovery, neostigmine (40 \u00b5g kg<sup>\u20131<\/sup>) can be given at the reappearance of TOF count of 4. In both scenarios, quantitative NMM should be continued until a TOF ratio more than 0.9 (TOF ratio 1.0 when using AMG monitoring) has been attained. Qualitative NMM with a PNS, however, may overestimate neostigmine-induced recovery, as fade following TOF-stimulation is no longer detectable for TOF-ratios more than 0.4.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref81\">81<\/a>\u2013<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref83\">83<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref97\">97<\/a><\/sup>&nbsp;For that reason, PNS are not suitable in this context.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a68f64a24181f71356b4075b1cb9a182 wp-block-paragraph\" id=\"tab5\">Table 5&nbsp;Prereversal train-of-four and neostigmine-induced recovery<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/images\/tab5.jpg\" alt=\"images\" \/><\/figure>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--bcaae1939c8ed719d61bd6a4344b4ee6 wp-block-paragraph\">Final remarks and discussion<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ca6b03251fd29b2e314036210480cc9b wp-block-paragraph\">We developed these first guidelines on the peri-operative management of neuromuscular blockade for the European Society of Anesthesiology and Intensive Care. The guidelines are intended to provide evidence-based recommendations to improve patient safety. To facilitate its implementation in current clinical practice, the guidance has been intentionally limited to three clinically relevant core issues: significance of neuromuscular blocking agents for tracheal intubation, contribution of neuromuscular blocking agents to improve surgical conditions and significance of NMM and pharmacological reversal to reduce residual paralysis and POPCs.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1107a1c7bed423b8edf9b2979aca5e08 wp-block-paragraph\">The main conclusion of the authors is that the decision making for any neuromuscular reversal strategy, that is neostigmine-based reversal, sugammadex-based reversal or spontaneous reversal, should be well founded on reliable quantitative NMM. The limitation of qualitative NMM with a PNS to detect a TOF ratio of at least 0.9 should be recognised. There is no way to confirm these levels of recovery by either tactile evaluation of TOF or DBS (double burst stimulation), as no fade can be detected when the TOF ratio exceeds 0.4 and 0.6, respectively.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref101\">101<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref102\">102<\/a><\/sup>&nbsp;Hence, detectable fade after TOF or DBS stimulation is a clear sign of inadequate neuromuscular recovery, but lack of fade does not exclude residual paralysis. Similarly, the use of 100-Hz, 5-s tetanus did not reliably exclude residual paralysis. It has a poor specificity, as about half of the patients without any degree of residual paralysis will exhibit manually detectable fade. In addition, one of four patients still had residual paralysis despite the absence of fade after a 100-Hz, 5-s stimulation.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref78\">78<\/a><\/sup>&nbsp;However, quantitative NMM is not a magic bullet either, providing reliable results automatically. Most devices need calibration or a baseline value to be determined before relaxation otherwise their performance is significantly reduced.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref78\">78<\/a><\/sup>&nbsp;It is not unusual in current clinical practice that quantitative NMM is applied only at the end of the surgical procedure, particularly if the same device is shared with several operating theatres. In this setting, however, even quantitative (uncalibrated, nonnormalised) NMM is insufficient to exclude residual paralysis reliably.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref78\">78<\/a><\/sup>&nbsp;As a consequence, the availability of quantitative NMM in each single operating theatre is a prerequisite for its appropriate use.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d1cd2475a77e6c1e5a7c3b97e01b6a58 wp-block-paragraph\">Recently, Schaefer&nbsp;<em>et al.<\/em><sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref103\">103<\/a><\/sup>&nbsp;examined the association between succinylcholine and POPC; they observed that of 244 850 adult patients, 5.4% experienced POPC; the higher the dose of succinylcholine, the higher the risk of POPC.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref103\">103<\/a><\/sup>&nbsp;This strongly implicates residual paralysis as an underlying mechanism. At first glance, this may be surprising, as generations of anaesthesiologists used succinylcholine for its unique properties of rapid onset and short duration. However, its pharmacodynamic profile is characterised by high inter-individual variability and data from the Danish Cholinesterase Research Unit identified a deficit in plasma butyrylcholinesterase activity as a major risk factor for unexpected residual paralysis, respiratory complications, and awareness during emergence after succinylcholine.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref104\">104<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref105\">105<\/a><\/sup>&nbsp;Moreover, lack of NMM increases the risk of these adverse events significantly.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref106\">106<\/a><\/sup>&nbsp;Consequently, neuromuscular transmission should be monitored quantitatively regardless of type of neuromuscular-blocking drug is used, even if only succinylcholine has been administered.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref107\">107<\/a><\/sup><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--69684c074048df84a78215420846a8c7 wp-block-paragraph\">Our findings confirmed that residual paralysis is more common after neostigmine-based reversal than after sugammadex, as it occurred in 2% of patients after sugammadex but in 24% when neostigmine was used.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--694747eb549fe2b577fb61f0c6110e73 wp-block-paragraph\">This corresponds to an absolute risk reduction of 22% and a NNT (number needed to treat) of 4.5. In other words, a reversal strategy based on sugammadex instead of neostigmine may prevent residual paralysis in one out of four or five patients; however, this is not the sole benefit, as convincing evidence also suggests a significant reduction of the incidence of POPC. Concerning the risk associated with both reversal strategies, a recent Cochrane review reported a better safety profile for sugammadex (risk ratio, 0.6; 95% CI, 0.49 to 0.74; 28 studies,&nbsp;<em>n<\/em>&nbsp;= 2298) compared with neostigmine.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref80\">80<\/a><\/sup>&nbsp;A few cases of anaphylaxis after sugammadex are reported. Recently, a retrospective multicentre observational study from Japan including 49 532 patients reported six cases of anaphylaxis attributable to sugammadex, whilst the 6th National Audit Project (NAP6) from the Royal College of Anaesthetists found a 10-fold lower incidence (one out of 64 121 patient).<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref108\">108<\/a>,<a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref109\">109<\/a><\/sup>&nbsp;It is certainly difficult to ascertain the true incidence of any rare adverse event; however, the risk of anaphylaxis alone should not be an over-riding factor in the choice of reversal agent.<sup><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#iref110\">110<\/a><\/sup><\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f8d13593218a73a08eb918c31b5eb947 wp-block-paragraph\">The implementation of these guidelines in current clinical practice is crucial to meaningfully improve patient care and outcomes. Hence, the task force proposes a bundle of measures to facilitate, accompany and monitor the implementation process. Amongst these, the following:<\/p>\n\n\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--5f3a827195ec504c2f1e3801e88ca1e0 wp-block-paragraph\">Limitations and further research<\/p>\n\n\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7a6bc3c7d55a4b988676799764a8b53c wp-block-paragraph\">In conclusion, there is convincing evidence that residual paralysis and relaxation-associated pulmonary complications are less common after sugammadex-based pharmacological reversal than after neostigmine. Moreover, reliable quantitative NMM is the principal prerequisite of any appropriate strategy for the peri-operative neuromuscular management, whether that is spontaneous recovery, sugammadex-based or neostigmine-based recovery.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c8265b7a26a1e99b064c64e542dc95f2 wp-block-paragraph\">Acknowledgements relating to this article<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ec0e390cef10691b772231b9d3e130ce wp-block-paragraph\">Assistance with the study: The authors wish to thank Janne Vendt (Cochrane Anaesthesia, Critical and Emergency Care Group (ACE), anaesthesiologist at Herlev Hospital, Herlev, Denmark) for conducting literature searches, and Pierre Harlet, Sophie Debouche and Saman Sepehr at the ESAIC Guidelines office for secretarial assistance.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d00f0bd672fda09873c62513203ad3dc wp-block-paragraph\">Financial support and sponsorship: The work was funded exclusively by ESAIC.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1e01acef98c9758cc411824a2909b694 wp-block-paragraph\">Conflicts of interest: TFB has received funding from MSD in the past 5 years to give international lectures and chair CME meetings.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--81969f51934f3b7d12f99bbd94f6d06f wp-block-paragraph\">RJJ has received consultation fees from Thermofisher, Baxter, Pfizer, MSD, BBraun, Astelas.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--05d7056eac4f2548bc683078da366b58 wp-block-paragraph\">MS has received consultation fees from Teleflex Medical, Verathon Medical, Deas Italia, MSD Italia, Baxter Italia, Boston Scientific France. He is the patent co-owner (no royalties) of DEAS Italia.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--5300f9f5ddf3f42d9b12320dc37c4a5f wp-block-paragraph\">DL is a member of Advisory board (Edwards Lifesciences, Medasense, Orion Pharma) and has received conference fees from Masimo, Edwards Lifesciences, LFB, Medasense, Orion Pharma<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2a95b1a20d2fc3c1dce82eeea9e59813 wp-block-paragraph\">HDDB has received research grants and funding from MSD to participate in CME meetings<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7e8f676a79d3066f93e311cf36bd9362 wp-block-paragraph\">None of the other authors report any conflict of interest related to this topic.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f4ecf159f00a89ad7e090e5db8653150 wp-block-paragraph\">References<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--af9da4b034de7f3f6c914289fa5515c7 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref1\">1<\/a>Kirmeier E, Eriksson LI, Lewald H,&nbsp;<em>et al.<\/em>&nbsp;Postanaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study.&nbsp;<em>Lancet Respir Med<\/em>&nbsp;2019;&nbsp;<strong>7<\/strong>:129\u2013140.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--94203d4d728163c5a621be7ea31952ec wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">2<\/a>Alexander R, Olufolabi AJ, Booth J,&nbsp;<em>et al.<\/em>&nbsp;Dosing study of remifentanil and propofol for tracheal intubation without the use of muscle relaxants.&nbsp;<em>Anaesthesia<\/em>&nbsp;1999;&nbsp;<strong>54<\/strong>:1037\u20131040.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--52e5be62149429411885ec6d6c805ced wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">3<\/a>Barbosa FT, Neto OBO, Barbosa LT,&nbsp;<em>et al.<\/em>&nbsp;[Effectiveness of magnesium sulfate compared to rocuronium for rapid sequence tracheal intubation in adults: clinical randomized trial].&nbsp;<em>Braz J Anesthesiol<\/em>&nbsp;2020;&nbsp;<strong>70<\/strong>:42\u201347.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--5298c181a4b8a31027fd189ce2aecc2b wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">4<\/a>Barclay K, Eggers K, Asai T. Low-dose rocuronium improves conditions for tracheal intubation after induction of anaesthesia with propofol and alfentanil.&nbsp;<em>Br J Anaesth<\/em>&nbsp;1997;&nbsp;<strong>78<\/strong>:92\u201394.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--077f75cf0c2419470584456be461c099 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">5<\/a>Beck GN, Masterson GR, Richards J, Bunting P. Comparison of intubation following propofol and alfentanil with intubation following thiopentone and suxamethonium.&nbsp;<em>Anaesthesia<\/em>&nbsp;1993;&nbsp;<strong>48<\/strong>:876\u2013880.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2da144e13adfa28738461ef2107efaac wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref6\">6<\/a>Bouvet L, Stoian A, Jacquot-Laperriere S,&nbsp;<em>et al.<\/em>&nbsp;Laryngeal injuries and intubating conditions with or without muscular relaxation: an equivalence study.&nbsp;<em>Can J Anaesth<\/em>&nbsp;2008;&nbsp;<strong>55<\/strong>:674\u2013684.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--96f17b7c1f7b670b58665f6bd7404688 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">7<\/a>Collins L, Prentice J, Vaghadia H. Tracheal intubation of outpatients with and without muscle relaxants.&nbsp;<em>Can J Anaesth<\/em>&nbsp;2000;&nbsp;<strong>47<\/strong>:427\u2013432.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--31cd8618c5621488a973d9d924dc3908 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref8\">8<\/a>Combes X, Andriamifidy L, Dufresne E,&nbsp;<em>et al.<\/em>&nbsp;Comparison of two induction regimens using or not using muscle relaxant: impact on postoperative upper airway discomfort.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2007;&nbsp;<strong>99<\/strong>:276\u2013281.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--87dcb6567d6d2c213aef7c1eaa589cb2 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">9<\/a>Dominici L, Gondret R, Dubos S,&nbsp;<em>et al.<\/em>&nbsp;[Intubation in otorhinolaryngologic surgery: propofol versus propofol-suxamethonium].&nbsp;<em>Ann Fr Anesth Reanim<\/em>&nbsp;1990;&nbsp;<strong>9<\/strong>:110\u2013114.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--78c3c7d3297fb7fdf01a3ca9ba5019df wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref10\">10<\/a>Gonzalez Obregon MP, Rivera Diaz RC, Ordonez Molina JE,&nbsp;<em>et al.<\/em>&nbsp;[Tracheal intubation quality under remifentanil-propofol with sevoflurane compared with remifentanil-propofol with rocuronium: a randomized double-blind clinical trial].&nbsp;<em>Rev Esp Anestesiol Reanim<\/em>&nbsp;2010;&nbsp;<strong>57<\/strong>:351\u2013356.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--473198660633beccb9ebda7b60b90358 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref11\">11<\/a>Gulhas N, Topal S, Erdogan Kayhan G,&nbsp;<em>et al.<\/em>&nbsp;Remifentanil without muscle relaxants for intubation in microlaryngoscopy: a double blind randomised clinical trial.&nbsp;<em>Eur Rev Med Pharmacol Sci<\/em>&nbsp;2013;&nbsp;<strong>17<\/strong>:1967\u20131973.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--95a7a4cb632ef304f1dc69a07c9ea71b wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">12<\/a>Hanna SF, Ahmad F, Pappas AL,&nbsp;<em>et al.<\/em>&nbsp;The effect of propofol\/remifentanil rapid-induction technique without muscle relaxants on intraocular pressure.&nbsp;<em>J Clin Anesth<\/em>&nbsp;2010;&nbsp;<strong>22<\/strong>:437\u2013442.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--797a49d940223c5d0ae5a041dea6c302 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">13<\/a>Harsten A, Gillberg L. Intubating conditions provided by propofol and alfentanil: acceptable, but not ideal.&nbsp;<em>Acta Anaesthesiol Scand<\/em>&nbsp;1997;&nbsp;<strong>41<\/strong>:985\u2013987.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--90213f1516cfba12d48088c7e1679cce wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">14<\/a>Iamaroon A, Pitimana-aree S, Prechawai C,&nbsp;<em>et al.<\/em>&nbsp;Endotracheal intubation with thiopental\/succinylcholine or sevoflurane-nitrous oxide anesthesia in adults: a comparative study.&nbsp;<em>Anesth Analg<\/em>&nbsp;2001;&nbsp;<strong>92<\/strong>:523\u2013528.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--25a26251c3da666bbd9cf319d296f985 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">15<\/a>Isesele T, Amadasun F, Edomwonyi N. Comparison of intubating conditions with propofol suxamethonium versus propofol-LIDOCAINE.&nbsp;<em>J West Afr Coll Surg<\/em>&nbsp;2012;&nbsp;<strong>2<\/strong>:51\u201367.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--5ce659ba1fcd71dba532574f22635782 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">16<\/a>Jiao J, Huang S, Chen Y,&nbsp;<em>et al.<\/em>&nbsp;Comparison of intubation conditions and apnea time after anesthesia induction with propofol\/remifentanil combined with or without small dose of succinylcholine.&nbsp;<em>Int J Clin Exp Med<\/em>&nbsp;2014;&nbsp;<strong>7<\/strong>:393\u2013399.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d8fa32772f2c2077b76ea9b097ad5e57 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">17<\/a>Kahwaji R, Bevan DR, Bikhazi G,&nbsp;<em>et al.<\/em>&nbsp;Dose-ranging study in younger adult and elderly patients of ORG 9487, a new, rapid-onset, short-duration muscle relaxant.&nbsp;<em>Anesth Analg<\/em>&nbsp;1997;&nbsp;<strong>84<\/strong>:1011\u20131018.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--253979d4e49fb3e4328912de971fa15b wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">18<\/a>Kirkegaard-Nielsen H, Caldwell JE, Berry PD. Rapid tracheal intubation with rocuronium: a probability approach to determining dose.&nbsp;<em>Anesthesiology<\/em>&nbsp;1999;&nbsp;<strong>91<\/strong>:131\u2013136.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--16d9199141d8e7c811110b9f01dfa503 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">19<\/a>Kohli M, Abbas H, Khan MP, Rana S. Comparison of intubating conditions following propofol and succinylcholine with propofol and fentanyl.&nbsp;<em>J Anaesthesiol Clin Pharmacol<\/em>&nbsp;2008;&nbsp;<strong>24<\/strong>:205\u2013209.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9f8bcbf74fdb7653227a8ff441f06161 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">20<\/a>Kopman AF, Khan NA, Neuman GG. Precurarization and priming: a theoretical analysis of safety and timing.&nbsp;<em>Anesth Analg<\/em>&nbsp;2001;&nbsp;<strong>93<\/strong>:1253\u20131256.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f95758148ad96a2eff6bf7d8b082c431 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">21<\/a>Lieutaud T, Billard V, Khalaf H, Debaene B. Muscle relaxation and increasing doses of propofol improve intubating conditions.&nbsp;<em>Can J Anaesth<\/em>&nbsp;2003;&nbsp;<strong>50<\/strong>:121\u2013126.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d7c90f96c166b47a17d30fa40c99b120 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">22<\/a>Lowry DW, Carroll MT, Mirakhur RK,&nbsp;<em>et al.<\/em>&nbsp;Comparison of sevoflurane and propofol with rocuronium for modified rapid-sequence induction of anaesthesia.&nbsp;<em>Anaesthesia<\/em>&nbsp;1999;&nbsp;<strong>54<\/strong>:247\u2013252.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1c50af7d720ae9804a89f496603ebc21 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">23<\/a>McNeil IA, Culbert B, Russell I. Comparison of intubating conditions following propofol and succinylcholine with propofol and remifentanil 2 micrograms kg-1 or 4 micrograms kg-1.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2000;&nbsp;<strong>85<\/strong>:623\u2013625.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--49180884b9ff80dbb497291333590deb wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref24\">24<\/a>Mencke T, Jacobs RM, Machmueller S,&nbsp;<em>et al.<\/em>&nbsp;Intubating conditions and side effects of propofol, remifentanil and sevoflurane compared with propofol, remifentanil and rocuronium: a randomised, prospective, clinical trial.&nbsp;<em>BMC Anesthesiol<\/em>&nbsp;2014;&nbsp;<strong>14<\/strong>:39.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--594ce6e3de2b3beb167caa39b65782d1 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref25\">25<\/a>Mencke T, Echternach M, Kleinschmidt S,&nbsp;<em>et al.<\/em>&nbsp;Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial.&nbsp;<em>Anesthesiology<\/em>&nbsp;2003;&nbsp;<strong>98<\/strong>:1049\u20131056.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b06e3bdbd1a783f1d1b92071decb18e3 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">26<\/a>Naguib M, Samarkandi A, Riad W, Alharby SW. Optimal dose of succinylcholine revisited.&nbsp;<em>Anesthesiology<\/em>&nbsp;2003;&nbsp;<strong>99<\/strong>:1045\u20131049.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--81cbccb27a14749a2650557366bbd3bb wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">27<\/a>Naguib M, Scamman FL, O&#8217;Sullivan C,&nbsp;<em>et al.<\/em>&nbsp;Predictive performance of three multivariate difficult tracheal intubation models: a double-blind, case-controlled study.&nbsp;<em>Anesth Analg<\/em>&nbsp;2006;&nbsp;<strong>102<\/strong>:818\u2013824.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ad84449efa7b50f68ef3f4f2f00cd0c1 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">28<\/a>Nimmo SM, McCann N, Broome IJ, Robb HM. Effectiveness and sequelae of very low-dose suxamethonium for nasal intubation.&nbsp;<em>Br J Anaesth<\/em>&nbsp;1995;&nbsp;<strong>74<\/strong>:31\u201334.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--e8de67199ba3ee4d549371774bdd0b85 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">29<\/a>Pang L, Zhuang YY, Dong S,&nbsp;<em>et al.<\/em>&nbsp;Intubation without muscle relaxation for suspension laryngoscopy: a randomized, controlled study.&nbsp;<em>Niger J Clin Pract<\/em>&nbsp;2014;&nbsp;<strong>17<\/strong>:456\u2013461.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--be9d038016eb46b82eaf25f46c0e4eda wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">30<\/a>Pino RM, Ali HH, Denman WT,&nbsp;<em>et al.<\/em>&nbsp;A comparison of the intubation conditions between mivacurium and rocuronium during balanced anesthesia.&nbsp;<em>Anesthesiology<\/em>&nbsp;1998;&nbsp;<strong>88<\/strong>:673\u2013678.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--339f171689e6ab3ebb38131ef01ffcb1 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">31<\/a>Rousseau JM, Lemardeley P, Giraud D,&nbsp;<em>et al.<\/em>&nbsp;[Endotracheal intubation under propofol with or without vecuronium].&nbsp;<em>Ann Fr Anesth Reanim<\/em>&nbsp;1995;&nbsp;<strong>14<\/strong>:261\u2013264.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a8a82bbd6122dcd497f1ccc055a9a8c1 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">32<\/a>Scheller MS, Zornow MH, Saidman LJ. Tracheal intubation without the use of muscle relaxants: a technique using propofol and varying doses of alfentanil.&nbsp;<em>Anesth Analg<\/em>&nbsp;1992;&nbsp;<strong>75<\/strong>:788\u2013793.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--365e911f7061a982d8a355ec57ef8bd1 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref33\">33<\/a>Schlaich N, Mertzlufft F, Soltesz S, Fuchs-Buder T. Remifentanil and propofol without muscle relaxants or with different doses of rocuronium for tracheal intubation in outpatient anaesthesia.&nbsp;<em>Acta Anaesthesiol Scand<\/em>&nbsp;2000;&nbsp;<strong>44<\/strong>:720\u2013726.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--e5a39a17b7651c545b07fa457e7ae14d wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">34<\/a>Sivalingam P, Kandasamy R, Dhakshinamoorthi P, Madhavan G. Tracheal intubation without muscle relaxant: a technique using sevoflurane vital capacity induction and alfentanil.&nbsp;<em>Anaesth Intensive Care<\/em>&nbsp;2001;&nbsp;<strong>29<\/strong>:383\u2013387.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9d76813210acb339d242e07cb4e6fcfb wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">35<\/a>Solt\u00e9sz S, Mencke T, Schlaich N, Fuchs-Buder T. Co-induction of anaesthesia with desflurane improves intubating conditions after low-dose rocuronium.&nbsp;<em>Clin Drug Invest<\/em>&nbsp;2001;&nbsp;<strong>21<\/strong>:409\u2013414.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--3f2ba1db0c55376834b917cfe907f4b1 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">36<\/a>Stevens JB, Vescovo MV, Harris KC,&nbsp;<em>et al.<\/em>&nbsp;Tracheal intubation using alfentanil and no muscle relaxant: is the choice of hypnotic important?&nbsp;<em>Anesth Analg<\/em>&nbsp;1997;&nbsp;<strong>84<\/strong>:1222\u20131226.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f3c3917732ad77a7344a815f469e38ec wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">37<\/a>Striebel HW, Holzl M, Rieger A, Brummer G. [Endotracheal intubation with propofol and fentanyl].&nbsp;<em>Anaesthesist<\/em>&nbsp;1995;&nbsp;<strong>44<\/strong>:809\u2013817.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--795547503b4788d55b78fe283efd2b7a wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">38<\/a>Wong AK, Teoh GS. Intubation without muscle relaxant: an alternative technique for rapid tracheal intubation.&nbsp;<em>Anaesth Intensive Care<\/em>&nbsp;1996;&nbsp;<strong>24<\/strong>:224\u2013230.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1a767515eb523b8f061fecc2a70a03c3 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref2\">39<\/a>Yazdi B, Khalili M, Dadashpour N<em>, et al<\/em>. The comparison of atracurium and remifentanil effect on jaw relaxation and tracheal intubation condition without muscle relaxant in patients undergoing elective surgery<em>. Acta Med Mediterranea<\/em>&nbsp;2016;&nbsp;<strong>32<\/strong>:1029\u20131032.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--219e10f9ac2ca40736bacca53edc53a7 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref40\">40<\/a>Sorensen MK, Bretlau C, Gatke MR,&nbsp;<em>et al.<\/em>&nbsp;Rapid sequence induction and intubation with rocuronium-sugammadex compared with succinylcholine: a randomized trial.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2012;&nbsp;<strong>108<\/strong>:682\u2013689.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--6b1a87ea180d0fccd471cedaab0efdf6 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref41\">41<\/a>Lundstrom LH, Moller AM, Rosenstock C,&nbsp;<em>et al.<\/em>&nbsp;Avoidance of neuromuscular blocking agents may increase the risk of difficult tracheal intubation: a cohort study of 103,812 consecutive adult patients recorded in the Danish Anaesthesia Database.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2009;&nbsp;<strong>103<\/strong>:283\u2013290.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c6fb303ccc3e2eb837a1531739a5c899 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref42\">42<\/a>Lundstrom LH, Duez CHV, Norskov AK,&nbsp;<em>et al<\/em>. Effects of avoidance or use of neuromuscular blocking agents on outcomes in tracheal intubation: a Cochrane systematic review.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2018;&nbsp;<strong>120<\/strong>:1381\u20131393.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--0426b2cd8bc6610758a16fbd73f9d656 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref43\">43<\/a>Tran DTT, Newton EK, Mount VAH,&nbsp;<em>et al.<\/em>&nbsp;Rocuronium vs. succinylcholine for rapid sequence intubation: a Cochrane systematic review.&nbsp;<em>Anaesthesia<\/em>&nbsp;2017;&nbsp;<strong>72<\/strong>:765\u2013777.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--70a8de8aadd8f97a0ca7f3d661192673 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref44\">44<\/a>Plaud B, Baillard C, Bourgain JL,&nbsp;<em>et al.<\/em>&nbsp;Guidelines on muscle relaxants and reversal in anaesthesia<em>. Anaesth Crit Care Pain Med<\/em>&nbsp;2020;&nbsp;<strong>39<\/strong>:125\u2013142.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--8a3ab5daed546dde7e025be2c7071f11 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref45\">45<\/a>Baete S, Vercruysse G, Vander Laenen M,&nbsp;<em>et al.<\/em>&nbsp;The effect of deep versus moderate neuromuscular block on surgical conditions and postoperative respiratory function in bariatric laparoscopic surgery: a randomized double blind clinical trial.&nbsp;<em>Anesth Analg<\/em>&nbsp;2017;&nbsp;<strong>124<\/strong>:1469\u20131475.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--94b2e0e0230a52af2ac87f09d2636222 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref46\">46<\/a>Barrio J, Errando CL, Garcia-Ramon J,&nbsp;<em>et al.<\/em>&nbsp;Influence of depth of neuromuscular blockade on surgical conditions during low-pressure pneumoperitoneum laparoscopic cholecystectomy: a randomized blinded study.&nbsp;<em>J Clin Anesth<\/em>&nbsp;2017;&nbsp;<strong>42<\/strong>:26\u201330.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--643ec7506d3e7b1670d2a7d8ba347920 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref46\">47<\/a>Barrio J, Errando CL, San Miguel G,&nbsp;<em>et al.<\/em>&nbsp;Effect of depth of neuromuscular blockade on the abdominal space during pneumoperitoneum establishment in laparoscopic surgery<em>. J Clin Anesth<\/em>&nbsp;2016;&nbsp;<strong>34<\/strong>:197\u2013203.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--fd4a848b7cd8fa06208a2262ca3cb883 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref48\">48<\/a>Blobner M, Frick CG, Stauble RB,&nbsp;<em>et al.<\/em>&nbsp;Neuromuscular blockade improves surgical conditions (NISCO).&nbsp;<em>Surg Endosc<\/em>&nbsp;2015;&nbsp;<strong>29<\/strong>:627\u2013636.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--43031a3311a0378ca2edb7c66bac98fd wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref49\">49<\/a>Bruintjes MHD, Krijtenburg P, Martini CH,&nbsp;<em>et al.<\/em>&nbsp;Efficacy of profound versus moderate neuromuscular blockade in enhancing postoperative recovery after laparoscopic donor nephrectomy: a randomised controlled trial.&nbsp;<em>Eur J Anaesthesiol<\/em>&nbsp;2019;&nbsp;<strong>36<\/strong>:494\u2013501.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d1cbcbabb1c438f0addf735e4537848c wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref45\">50<\/a>Choi BM, Ki SH, Lee YH,&nbsp;<em>et al.<\/em>&nbsp;Effects of depth of neuromuscular block on postoperative pain during laparoscopic gastrectomy: a randomised controlled trial.&nbsp;<em>Eur J Anaesthesiol<\/em>&nbsp;2019;&nbsp;<strong>36<\/strong>:863\u2013870.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1ed1634c4962c0d5aaf3e3b1d6d775ea wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref45\">51<\/a>Dubois PE, Putz L, Jamart J,&nbsp;<em>et al.<\/em>&nbsp;Deep neuromuscular block improves surgical conditions during laparoscopic hysterectomy: a randomised controlled trial.&nbsp;<em>Eur J Anaesthesiol<\/em>&nbsp;2014;&nbsp;<strong>31<\/strong>:430\u2013436.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--51624c23b3c87e4f21dfc20fb64d28b1 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref52\">52<\/a>Fuchs-Buder T, Schmartz D, Baumann C,&nbsp;<em>et al.<\/em>&nbsp;Deep neuromuscular blockade improves surgical conditions during gastric bypass surgery for morbid obesity: a randomised controlled trial.&nbsp;<em>Eur J Anaesthesiol<\/em>&nbsp;2019;&nbsp;<strong>36<\/strong>:486\u2013493.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b0ed0b0aa32a5e07b7b9439a4275bdbe wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref53\">53<\/a>Honing GHM, Martini CH, Olofsen E,&nbsp;<em>et al.<\/em>&nbsp;Deep neuromuscular block does not improve surgical conditions in patients receiving sevoflurane anaesthesia for laparoscopic renal surgery.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2021;&nbsp;<strong>126<\/strong>:377\u2013385.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--23811ee6b9a86457c4ea99b165d9a7c6 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref45\">54<\/a>Kim HJ, Lee KY, Kim MH,&nbsp;<em>et al.<\/em>&nbsp;Effects of deep vs moderate neuromuscular block on the quality of recovery after robotic gastrectomy.&nbsp;<em>Acta Anaesthesiol Scand<\/em>&nbsp;2019;&nbsp;<strong>63<\/strong>:306\u2013313.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--5ac702082af0886603b458057efedb2c wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref55\">55<\/a>Kim MH, Lee KY, Lee KY,&nbsp;<em>et al.<\/em>&nbsp;Maintaining optimal surgical conditions with low insufflation pressures is possible with deep neuromuscular blockade during laparoscopic colorectal surgery: a prospective, randomized, double-blind parallel-group clinical trial.&nbsp;<em>Medicine (Baltimore)<\/em>&nbsp;2016;&nbsp;<strong>95<\/strong>:e2920.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--712692b5e648c14f87e1ac38d9b979f3 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref56\">56<\/a>King M, Sujirattanawimol N, Danielson DR,&nbsp;<em>et al.<\/em>&nbsp;Requirements for muscle relaxants during radical retropubic prostatectomy.&nbsp;<em>Anesthesiology<\/em>&nbsp;2000;&nbsp;<strong>93<\/strong>:1392\u20131397.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--6850181f7e416686c5a9eefc3159b1e0 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref57\">57<\/a>Koo BW, Oh AY, Na HS<em>, et al<\/em>. Effects of depth of neuromuscular block on surgical conditions during laparoscopic colorectal surgery: a randomised controlled trial.&nbsp;<em>Anaesthesia<\/em>&nbsp;2018;&nbsp;<strong>73<\/strong>:1090\u20131096.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--88da4999e6eff8d6e12e9a63e2f901df wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref57\">58<\/a>Koo BW, Oh AY, Seo KS,&nbsp;<em>et al.<\/em>&nbsp;Randomized clinical trial of moderate versus deep neuromuscular block for low-pressure pneumoperitoneum during laparoscopic cholecystectomy.&nbsp;<em>World J Surg<\/em>&nbsp;2016;&nbsp;<strong>40<\/strong>:2898\u20132903.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c8add308c1d94891ede3467e8e485a25 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref57\">59<\/a>Koo CH, Chung SH, Kim BG,&nbsp;<em>et al.<\/em>&nbsp;Comparison between the effects of deep and moderate neuromuscular blockade during transurethral resection of bladder tumor on endoscopic surgical condition and recovery profile: a prospective, randomized, and controlled trial.&nbsp;<em>World J Urol<\/em>&nbsp;2019;&nbsp;<strong>37<\/strong>:359\u2013365.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--34c10b7028e66e258b94d766921bc876 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref60\">60<\/a>Leeman M, Biter LU, Apers JA,&nbsp;<em>et al.<\/em>&nbsp;Low-pressure pneumoperitoneum with deep neuromuscular blockade in metabolic surgery to reduce postoperative pain: a randomized pilot trial.&nbsp;<em>Surg Endosc<\/em>&nbsp;2021;&nbsp;<strong>35<\/strong>:2838\u20132845.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f955c711e9ee977e422f58d5a81804c3 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref61\">61<\/a>Madsen MV, Gatke MR, Springborg HH,&nbsp;<em>et al.<\/em>&nbsp;Optimising abdominal space with deep neuromuscular blockade in gynaecologic laparoscopy: a randomised, blinded crossover study.&nbsp;<em>Acta Anaesthesiol Scand<\/em>&nbsp;2015;&nbsp;<strong>59<\/strong>:441\u2013447.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--53cd3afd1d2ca6bb3a71eea974ff4ad9 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref62\">62<\/a>Madsen MV, Istre O, Staehr-Rye AK,&nbsp;<em>et al.<\/em>&nbsp;Postoperative shoulder pain after laparoscopic hysterectomy with deep neuromuscular blockade and low-pressure pneumoperitoneum: a randomised controlled trial.&nbsp;<em>Eur J Anaesthesiol<\/em>&nbsp;2016;&nbsp;<strong>33<\/strong>:341\u2013347.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--fa2ca89dd3a944ed641d08c4ddc96cbc wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref63\">63<\/a>Madsen MV, Scheppan S, Mork E,&nbsp;<em>et al.<\/em>&nbsp;Influence of deep neuromuscular block on the surgeons assessment of surgical conditions during laparotomy: a randomized controlled double blinded trial with rocuronium and sugammadex.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2017;&nbsp;<strong>119<\/strong>:435\u2013442.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--389eae9e48320d51fd25adce3aadbb8b wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref62\">64<\/a>Martini CH, Boon M, Bevers RF,&nbsp;<em>et al.<\/em>&nbsp;Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2014;&nbsp;<strong>112<\/strong>:498\u2013505.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--fb049716a17f7feea6fb4016743afa08 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref62\">65<\/a>Ozdemir-van Brunschot DMD, Braat AE, van der Jagt MFP,&nbsp;<em>et al.<\/em>&nbsp;Deep neuromuscular blockade improves surgical conditions during low-pressure pneumoperitoneum laparoscopic donor nephrectomy.&nbsp;<em>Surg Endosc<\/em>&nbsp;2018;&nbsp;<strong>32<\/strong>:245\u2013251.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b1650b83131c4f864c23c9204a40a042 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref66\">66<\/a>Rosenberg J, Herring WJ, Blobner M,&nbsp;<em>et al.<\/em>&nbsp;Deep neuromuscular blockade improves laparoscopic surgical conditions: a randomized controlled study.&nbsp;<em>Adv Ther<\/em>&nbsp;2017;&nbsp;<strong>34<\/strong>:925\u2013936.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--4316e2010000f11baed12b392d29b475 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref67\">67<\/a>Soderstrom CM, Borregaard Medici R, Assadzadeh S,&nbsp;<em>et al.<\/em>&nbsp;Deep neuromuscular blockade and surgical conditions during laparoscopic ventral hernia repair: a randomised, blinded study.&nbsp;<em>Eur J Anaesthesiol<\/em>&nbsp;2018;&nbsp;<strong>35<\/strong>:876\u2013882.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--93ff1bb743c992f90f996dcf25596549 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref68\">68<\/a>Staehr-Rye AK, Rasmussen LS, Rosenberg J,&nbsp;<em>et al.<\/em>&nbsp;Surgical space conditions during low-pressure laparoscopic cholecystectomy with deep versus moderate neuromuscular blockade: a randomized clinical study.&nbsp;<em>Anesth Analg<\/em>&nbsp;2014;&nbsp;<strong>119<\/strong>:1084\u20131092.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--954b354ddb88322ed455d59a7b0b0b95 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref69\">69<\/a>Torensma B, Martini CH, Boon M,&nbsp;<em>et al.<\/em>&nbsp;Deep neuromuscular block improves surgical conditions during bariatric surgery and reduces postoperative pain: a randomized double blind controlled trial.&nbsp;<em>PLoS One<\/em>&nbsp;2016;&nbsp;<strong>11<\/strong>:e0167907.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--fdfb0e6b48d59cd8a6550abcae6ac480 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref70\">70<\/a>Veelo DP, Gisbertz SS, Binnekade JM,&nbsp;<em>et al.<\/em>&nbsp;On-demand versus continuous rocuronium infusion for deep neuromuscular relaxation in patients undergoing thoraco-laparoscopic esophagectomy: a randomized-controlled clinical trial (DEPTH).&nbsp;<em>Can J Anaesth<\/em>&nbsp;2019;&nbsp;<strong>66<\/strong>:1062\u20131074.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b81805a04a25b522b1d05c36c583ac27 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref71\">71<\/a>Mortensen CR, Berg H, el-Mahdy A, Viby-Mogensen J. Perioperative monitoring of neuromuscular transmission using acceleromyography prevents residual neuromuscular block following pancuronium.&nbsp;<em>Acta Anaesthesiol Scand<\/em>&nbsp;1995;&nbsp;<strong>39<\/strong>:797\u2013801.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9db3d07f19c3a0dca47988038cfe02e1 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref72\">72<\/a>Gatke MR, Viby-Mogensen J, Rosenstock C,&nbsp;<em>et al.<\/em>&nbsp;Postoperative muscle paralysis after rocuronium: less residual block when acceleromyography is used.&nbsp;<em>Acta Anaesthesiol Scand<\/em>&nbsp;2002;&nbsp;<strong>46<\/strong>:207\u2013213.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2e2c7e7c365a27c73c1933dcf59bf58a wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref71\">73<\/a>Murphy GS, Szokol JW, Marymont JH,&nbsp;<em>et al.<\/em>&nbsp;Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit.&nbsp;<em>Anesthesiology<\/em>&nbsp;2008;&nbsp;<strong>109<\/strong>:389\u2013398.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c2ee1cf10b8730432970c997be07c059 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref71\">74<\/a>Murphy GS, Szokol JW, Avram MJ,&nbsp;<em>et al.<\/em>&nbsp;Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period.&nbsp;<em>Anesthesiology<\/em>&nbsp;2011;&nbsp;<strong>115<\/strong>:946\u2013954.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--dc141f50b346349aa6afc6343e94c38f wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref71\">75<\/a>Wardhana A, Kurniawaty J, Uyun Y. Optimised reversal without train-of-four monitoring versus reversal using quantitative train-of-four monitoring: an equivalence study.&nbsp;<em>Indian J Anaesth<\/em>&nbsp;2019;&nbsp;<strong>63<\/strong>:361\u2013367.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b216c3325ee27ff9d2394ee9fae302d6 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref76\">76<\/a>Domenech G, Kampel MA, Garcia Guzzo ME,&nbsp;<em>et al.<\/em>&nbsp;Usefulness of intraoperative neuromuscular blockade monitoring and reversal agents for postoperative residual neuromuscular blockade: a retrospective observational study.&nbsp;<em>BMC Anesthesiol<\/em>&nbsp;2019;&nbsp;<strong>19<\/strong>:143.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b37b5f96a92cf201528b2fa088e895ae wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref77\">77<\/a>Carvalho H, Verdonck M, Cools W,&nbsp;<em>et al.<\/em>&nbsp;Forty years of neuromuscular monitoring and postoperative residual curarisation: a meta-analysis and evaluation of confidence in network meta-analysis.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2020;&nbsp;<strong>125<\/strong>:466\u2013482.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--3afd77edbccbaabbd9bcba514082cbae wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref78\">78<\/a>Samet A, Capron F, Alla F,&nbsp;<em>et al.<\/em>&nbsp;Single acceleromyographic train-of-four, 100-Hertz tetanus or double-burst stimulation: which test performs better to detect residual paralysis?&nbsp;<em>Anesthesiology<\/em>&nbsp;2005;&nbsp;<strong>102<\/strong>:51\u201356.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--49401682b55ebe7d27b87231dd71a42a wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref79\">79<\/a>Capron F, Alla F, Hottier C,&nbsp;<em>et al.<\/em>&nbsp;Can acceleromyography detect low levels of residual paralysis? A probability approach to detect a mechanomyographic train-of-four ratio of 0.9.&nbsp;<em>Anesthesiology<\/em>&nbsp;2004;&nbsp;<strong>100<\/strong>:1119\u20131124.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--8ab2b9d2d5657d6e4b708050c3f0251d wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref80\">80<\/a>Hristovska AM, Duch P, Allingstrup M, Afshari A. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis.&nbsp;<em>Anaesthesia<\/em>&nbsp;2018;&nbsp;<strong>73<\/strong>:631\u2013641.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c046498d929dae27bc097bf273152ac3 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref81\">81<\/a>Kaufhold N, Schaller SJ, Stauble CG,&nbsp;<em>et al.<\/em>&nbsp;Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)dagger.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2016;&nbsp;<strong>116<\/strong>:233\u2013240.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--5f15258ba463ca93ada464a9aaa02566 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref82\">82<\/a>Pongracz A, Szatmari S, Nemes R,&nbsp;<em>et al.<\/em>&nbsp;Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation.&nbsp;<em>Anesthesiology<\/em>&nbsp;2013;&nbsp;<strong>119<\/strong>:36\u201342.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a8f4ccc259e907fdc55c9bc26303b637 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref83\">83<\/a>Asztalos L, Szabo-Maak Z, Gajdos A,&nbsp;<em>et al.<\/em>&nbsp;Reversal of vecuronium-induced neuromuscular blockade with low-dose sugammadex at train-of-four count of four: a randomized controlled trial.&nbsp;<em>Anesthesiology<\/em>&nbsp;2017;&nbsp;<strong>127<\/strong>:441\u2013449.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--4d65e8daff6ce2c83ebc31e9fd6d3cd3 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref84\">84<\/a>Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block.&nbsp;<em>Anesthesiology<\/em>&nbsp;2010;&nbsp;<strong>113<\/strong>:1054\u20131060.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d97c1d108cfac21725a278898335c755 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref85\">85<\/a>Blobner M, Eriksson LI, Scholz J,&nbsp;<em>et al.<\/em>&nbsp;Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.&nbsp;<em>Eur J Anaesthesiol<\/em>&nbsp;2010;&nbsp;<strong>27<\/strong>:874\u2013881.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--558828a0fed1dbcb100a92abbac7a2f6 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref85\">86<\/a>Khuenl-Brady KS, Wattwil M, Vanacker BF,&nbsp;<em>et al.<\/em>&nbsp;Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.&nbsp;<em>Anesth Analg<\/em>&nbsp;2010;&nbsp;<strong>110<\/strong>:64\u201373.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--fec63e6de5ee7bc20947374187502e84 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref85\">87<\/a>Wu X, Oerding H, Liu J,&nbsp;<em>et al.<\/em>&nbsp;Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects.&nbsp;<em>BMC Anesthesiol<\/em>&nbsp;2014;&nbsp;<strong>14<\/strong>:53.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b3a252ba4b0bf126864a6c35f9fb6502 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref85\">88<\/a>Brueckmann B, Sasaki N, Grobara P,&nbsp;<em>et al.<\/em>&nbsp;Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2015;&nbsp;<strong>115<\/strong>:743\u2013751.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--8bcf3badabfa4ab5cbf3478de37f5384 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref89\">89<\/a>Martinez-Ubieto J, Ortega-Lucea S, Pascual-Bellosta A,&nbsp;<em>et al.<\/em>&nbsp;Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex.&nbsp;<em>Minerva Anestesiol<\/em>&nbsp;2016;&nbsp;<strong>82<\/strong>:735\u2013742.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a3928e5ddbc7867f7e7cd47a3c7e476e wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref85\">90<\/a>Nemes R, Fulesdi B, Pongracz A,&nbsp;<em>et al<\/em>. Impact of reversal strategies on the incidence of postoperative residual paralysis after rocuronium relaxation without neuromuscular monitoring: a partially randomised placebo controlled trial.&nbsp;<em>Eur J Anaesthesiol<\/em>&nbsp;2017;&nbsp;<strong>34<\/strong>:609\u2013616.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7ccf436db80a670f64f9029d03a0592d wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref85\">91<\/a>Lee YJ, Oh AY, Koo BW,&nbsp;<em>et al.<\/em>&nbsp;Postoperative residual neuromuscular blockade after reversal based on a qualitative peripheral nerve stimulator response: a randomised controlled trial.&nbsp;<em>Eur J Anaesthesiol<\/em>&nbsp;2020;&nbsp;<strong>37<\/strong>:196\u2013202.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--42b42e55163b91bcd005b332d552d376 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref92\">92<\/a>Togioka BM, Yanez D, Aziz MF,&nbsp;<em>et al.<\/em>&nbsp;Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2020;&nbsp;<strong>124<\/strong>:553\u2013561.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d952cd9915d26c1952944a011d632a63 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref93\">93<\/a>Bartels K, Hunter JM. Neostigmine versus sugammadex: the tide may be turning, but we still need to navigate the winds.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2020;&nbsp;<strong>124<\/strong>:504\u2013507.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--933ccc378282a3091428125bc87efd6a wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref94\">94<\/a>Kheterpal S, Vaughn MT, Dubovoy TZ,&nbsp;<em>et al.<\/em>&nbsp;Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): a multicenter matched cohort analysis.&nbsp;<em>Anesthesiology<\/em>&nbsp;2020;&nbsp;<strong>132<\/strong>:1371\u20131381.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--5fd601b25ea05f5ff84afd54e5979332 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref95\">95<\/a>Krause M, McWilliams SK, Bullard KJ,&nbsp;<em>et al.<\/em>&nbsp;Neostigmine versus sugammadex for reversal of neuromuscular blockade and effects on reintubation for respiratory failure or newly initiated noninvasive ventilation: an interrupted time series design.&nbsp;<em>Anesth Analg<\/em>&nbsp;2020;&nbsp;<strong>131<\/strong>:141\u2013151.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--36fbb3892422c062131a91a47c6201cd wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref96\">96<\/a>Blobner M, Hunter JM, Meistelman C,&nbsp;<em>et al.<\/em>&nbsp;Use of a train-of-four ratio of 0.95 versus 0 9 for tracheal extubation: an exploratory analysis of POPULAR data.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2020;&nbsp;<strong>124<\/strong>:63\u201372.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7e35b3041d3100149dcd143719c62cca wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref97\">97<\/a>Thilen SR, Ng IC, Cain KC,&nbsp;<em>et al.<\/em>&nbsp;Management of rocuronium neuromuscular block using a protocol for qualitative monitoring and reversal with neostigmine.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2018;&nbsp;<strong>121<\/strong>:367\u2013377.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--60cadddfe360d96a9458f287b9fa92ca wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref98\">98<\/a>Baurain MJ, Dernovoi BS, D&#8217;Hollander AA,&nbsp;<em>et al.<\/em>&nbsp;Conditions to optimise the reversal action of neostigmine upon a vecuronium-induced neuromuscular block.&nbsp;<em>Acta Anaesthesiol Scand<\/em>&nbsp;1996;&nbsp;<strong>40<\/strong>:574\u2013578.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--81aa75d2a18069c6bc4aade30e42fa9b wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref98\">99<\/a>Fuchs-Buder T, Meistelman C, Alla F,&nbsp;<em>et al.<\/em>&nbsp;Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose-effect relationship for neostigmine.&nbsp;<em>Anesthesiology<\/em>&nbsp;2010;&nbsp;<strong>112<\/strong>:34\u201340.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ffa84ae1138a92108afabf7714952f62 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref100\">100<\/a>Kirkegaard H, Heier T, Caldwell JE. Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block.&nbsp;<em>Anesthesiology<\/em>&nbsp;2002;&nbsp;<strong>96<\/strong>:45\u201350.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9b1a4572a18383f1fdead480a3ef0f6a wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref101\">101<\/a>Drenck NE, Ueda N, Olsen NV,&nbsp;<em>et al.<\/em>&nbsp;Manual evaluation of residual curarization using double burst stimulation: a comparison with train-of-four.&nbsp;<em>Anesthesiology<\/em>&nbsp;1989;&nbsp;<strong>70<\/strong>:578\u2013581.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--bc85491fe5140f56d037411ce893bb9e wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref102\">102<\/a>Ueda N, Muteki T, Tsuda H,&nbsp;<em>et al.<\/em>&nbsp;Is the diagnosis of significant residual neuromuscular blockade improved by using double-burst nerve stimulation?&nbsp;<em>Eur J Anaesthesiol<\/em>&nbsp;1991;&nbsp;<strong>8<\/strong>:213\u2013218.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--3520a535434e89ffbf617af49afe9e47 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref103\">103<\/a>Schaefer MS, Hammer M, Santer P<em>, et al<\/em>. Succinylcholine and postoperative pulmonary complications: a retrospective cohort study using registry data from two hospital networks.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2020;&nbsp;<strong>125<\/strong>:629\u2013636.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--76fbb821c55fb3bb85958309e6f5d03e wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref104\">104<\/a>Dell-Kuster S, Levano S, Burkhart CS,&nbsp;<em>et al.<\/em>&nbsp;Predictors of the variability in neuromuscular block duration following succinylcholine: a prospective, observational study.&nbsp;<em>Eur J Anaesthesiol<\/em>&nbsp;2015;&nbsp;<strong>32<\/strong>:687\u2013696.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2c0bddfe3af533b956d7946cead32f25 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref105\">105<\/a>Thomsen JL, Nielsen CV, Eskildsen KZ,&nbsp;<em>et al.<\/em>&nbsp;Awareness during emergence from anaesthesia: significance of neuromuscular monitoring in patients with butyrylcholinesterase deficiency.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2015;&nbsp;<strong>115 (Suppl 1<\/strong>):i78\u2013i88.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2e29f8a2f05dbf67ba1152daccf0b836 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref106\">106<\/a>Thomsen JL, Nielsen CV, Palmqvist DF, Gatke MR. Premature awakening and underuse of neuromuscular monitoring in a registry of patients with butyrylcholinesterase deficiency.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2015;&nbsp;<strong>115 (Suppl 1<\/strong>):i89\u2013i94.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--467388c3c1800ac312e8f6aa319f8be0 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref107\">107<\/a>Schmartz D, Chenard L, Baumann C, Fuchs-Buder T. A modified train-of-four ratio to assess recovery from depolarizing neuromuscular blockade after succinylcholine, a prospective observational study.&nbsp;<em>J Clin Monit Comput<\/em>&nbsp;2021;&nbsp;<strong>35<\/strong>:1133\u20131138.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--3fad491901f6e913e242faf46c185b03 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref108\">108<\/a>Orihara M, Takazawa T, Horiuchi T,&nbsp;<em>et al.<\/em>&nbsp;Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2020;&nbsp;<strong>124<\/strong>:154\u2013163.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f41a4f014089b7145f4e0d22e11635ef wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref109\">109<\/a>Harper NJN, Cook TM, Garcez T,&nbsp;<em>et al.<\/em>&nbsp;Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6).&nbsp;<em>Br J Anaesth<\/em>&nbsp;2018;&nbsp;<strong>121<\/strong>:159\u2013171.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--875ad9642d34bc6cd82fced0072b4d76 wp-block-paragraph\"><a href=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/article.php#ref110\">110<\/a>de Boer HD, Hunter JM. Sugammadex or neostigmine: should potential anaphylaxis be the overriding factor in the choice of a reversal drug? Comment on Br J Anaesth 2020; 124:154-63.&nbsp;<em>Br J Anaesth<\/em>&nbsp;2020;&nbsp;<strong>125:<\/strong>&nbsp;e220\u2013e221.<\/p>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--43f849bfb21ca7ac250a56ed91424939 wp-block-paragraph\">This material is provided by MSD as a professional service to the medical community. Information related to any product(s) may not be consistent with the prescribing information. Please consult the full prescribing information for approved information on any products discussed in this publication and before prescribing.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n\n<p class=\"mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--6837ee09a5242bd824733d6414529427 wp-block-paragraph\" id=\"bottom_p\">Copyright \u00a9 2022 European Society of Anaesthesiology and Intensive Care<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Reprinted from EUROPEAN&nbsp;JOURNAL OF&nbsp;ANAESTHESIOLOGY November 16, 2022 Copyright \u00a9 2022 European Society of Anaesthesiology and Intensive Care Published by Lippincott [&hellip;]<\/p>\n","protected":false},"author":46316,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","primary_tag":0,"editor_notices":[],"mconnectHideShareThis":true,"footnotes":"","mconnectIsArchiveTemplate":false,"mconnectArchiveFiltersDisabled":false,"mconnectArchiveLockAllPresetFilters":false,"mconnectArchiveHidePageSubmenu":false,"mconnectArchiveShowParentPageOnly":false,"mconnectArchiveDefaultOrder":"DESC","mconnectArchiveDefaultOrderBy":"date","mconnectArchivePostsPerPage":12,"mconnectArchivePostTypes":[],"mconnectArchiveAllowFilterBy":["category","tx-content-type","tx-product","tx-pathology","tx-active-ingredient","tx-therapeutic-area"],"mconnectArchiveTaxonomyOrder":[],"mconnectArchiveFilterSorting":["is_keyword"],"mconnectArchiveContentItemStyle":{"showExcerpt":true,"showImage":true,"showIcon":false,"showPrimaryTag":true,"showBorder":false,"showDates":false,"showCta":true,"isCard":false,"hasBackground":false,"showMetadata":true},"mconnectArchiveLayout":{"type":"list","hasFeatured":false},"mconnectDynamicTaxonomyEntities":[],"mconnectArchiveTerms_category":[],"mconnectArchiveAllowTerms_category":[],"mconnectArchiveTerms_tx-content-type":[],"mconnectArchiveAllowTerms_tx-content-type":[],"mconnectArchiveTerms_tx-product":[],"mconnectArchiveAllowTerms_tx-product":[],"mconnectArchiveTerms_tx-pathology":[],"mconnectArchiveAllowTerms_tx-pathology":[],"mconnectArchiveTerms_tx-active-ingredient":[],"mconnectArchiveAllowTerms_tx-active-ingredient":[],"mconnectArchiveTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_dynamic-taxonomy":[],"mconnectArchiveLegacyDefaultTermsApplied":false,"mconnectContentUpdatesPerPage":10,"mconnectContentUpdatesViewMoreUrl":"","mconnectContentUpdatesTerms_tx-content-type":[],"mconnectContentUpdatesTerms_tx-product":[],"mconnectContentUpdatesTerms_tx-pathology":[],"mconnectContentUpdatesTerms_tx-active-ingredient":[],"mconnectContentUpdatesTerms_tx-therapeutic-area":[],"sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[],"tags":[],"ga4_page_audience":[1187],"ga4_page_birn_id":[],"ga4_page_branding":[],"ga4_page_businessunit":[],"ga4_page_campaign":[],"ga4_page_content_purpose":[],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[],"ga4_page_product":[],"ga4_page_region":[921],"ga4_page_therapeuticarea":[],"tx-therapeutic-area":[],"tx-product":[],"tx-pathology":[],"tx-content-type":[],"tx-active-ingredient":[],"mhh-area-of-interest":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-21277","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gu\u00eda ESAIC - MConnect Cenca Spanish<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gu\u00eda ESAIC - MConnect Cenca Spanish\" \/>\n<meta property=\"og:description\" content=\"Reprinted from EUROPEAN&nbsp;JOURNAL OF&nbsp;ANAESTHESIOLOGY November 16, 2022 Copyright \u00a9 2022 European Society of Anaesthesiology and Intensive Care Published by Lippincott [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/\" \/>\n<meta property=\"og:site_name\" content=\"MConnect Cenca Spanish\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-06T20:21:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/images\/logo1.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"45 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/guia-esaic-wp-0231\\\/\",\"url\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/guia-esaic-wp-0231\\\/\",\"name\":\"Gu\u00eda ESAIC - MConnect Cenca Spanish\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/guia-esaic-wp-0231\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/guia-esaic-wp-0231\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/eorder.sheridan.com\\\/3_0\\\/app\\\/orders\\\/13615\\\/images\\\/logo1.jpg\",\"datePublished\":\"2023-03-01T15:35:22+00:00\",\"dateModified\":\"2023-09-06T20:21:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/guia-esaic-wp-0231\\\/#breadcrumb\"},\"inLanguage\":\"es-CO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/guia-esaic-wp-0231\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-CO\",\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/guia-esaic-wp-0231\\\/#primaryimage\",\"url\":\"https:\\\/\\\/eorder.sheridan.com\\\/3_0\\\/app\\\/orders\\\/13615\\\/images\\\/logo1.jpg\",\"contentUrl\":\"https:\\\/\\\/eorder.sheridan.com\\\/3_0\\\/app\\\/orders\\\/13615\\\/images\\\/logo1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/guia-esaic-wp-0231\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gu\u00eda ESAIC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/\",\"name\":\"MConnect Cenca Spanish\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-CO\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/#organization\",\"name\":\"MConnect Cenca Spanish\",\"url\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-CO\",\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/wp-content\\\/uploads\\\/sites\\\/77\\\/2022\\\/07\\\/logo_tcm2359-1256911.png\",\"contentUrl\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/wp-content\\\/uploads\\\/sites\\\/77\\\/2022\\\/07\\\/logo_tcm2359-1256911.png\",\"width\":152,\"height\":48,\"caption\":\"MConnect Cenca Spanish\"},\"image\":{\"@id\":\"https:\\\/\\\/msdconecta.co.cr\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gu\u00eda ESAIC - MConnect Cenca Spanish","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/","og_locale":"es_ES","og_type":"article","og_title":"Gu\u00eda ESAIC - MConnect Cenca Spanish","og_description":"Reprinted from EUROPEAN&nbsp;JOURNAL OF&nbsp;ANAESTHESIOLOGY November 16, 2022 Copyright \u00a9 2022 European Society of Anaesthesiology and Intensive Care Published by Lippincott [&hellip;]","og_url":"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/","og_site_name":"MConnect Cenca Spanish","article_modified_time":"2023-09-06T20:21:24+00:00","og_image":[{"url":"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/images\/logo1.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"45 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/","url":"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/","name":"Gu\u00eda ESAIC - MConnect Cenca Spanish","isPartOf":{"@id":"https:\/\/msdconecta.co.cr\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/#primaryimage"},"image":{"@id":"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/#primaryimage"},"thumbnailUrl":"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/images\/logo1.jpg","datePublished":"2023-03-01T15:35:22+00:00","dateModified":"2023-09-06T20:21:24+00:00","breadcrumb":{"@id":"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/#breadcrumb"},"inLanguage":"es-CO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/"]}]},{"@type":"ImageObject","inLanguage":"es-CO","@id":"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/#primaryimage","url":"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/images\/logo1.jpg","contentUrl":"https:\/\/eorder.sheridan.com\/3_0\/app\/orders\/13615\/images\/logo1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/msdconecta.co.cr\/es\/guia-esaic-wp-0231\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/msdconecta.co.cr\/es\/"},{"@type":"ListItem","position":2,"name":"Gu\u00eda ESAIC"}]},{"@type":"WebSite","@id":"https:\/\/msdconecta.co.cr\/es\/#website","url":"https:\/\/msdconecta.co.cr\/es\/","name":"MConnect Cenca Spanish","description":"","publisher":{"@id":"https:\/\/msdconecta.co.cr\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/msdconecta.co.cr\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-CO"},{"@type":"Organization","@id":"https:\/\/msdconecta.co.cr\/es\/#organization","name":"MConnect Cenca Spanish","url":"https:\/\/msdconecta.co.cr\/es\/","logo":{"@type":"ImageObject","inLanguage":"es-CO","@id":"https:\/\/msdconecta.co.cr\/es\/#\/schema\/logo\/image\/","url":"https:\/\/msdconecta.co.cr\/es\/wp-content\/uploads\/sites\/77\/2022\/07\/logo_tcm2359-1256911.png","contentUrl":"https:\/\/msdconecta.co.cr\/es\/wp-content\/uploads\/sites\/77\/2022\/07\/logo_tcm2359-1256911.png","width":152,"height":48,"caption":"MConnect Cenca Spanish"},"image":{"@id":"https:\/\/msdconecta.co.cr\/es\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/pages\/21277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/users\/46316"}],"replies":[{"embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/comments?post=21277"}],"version-history":[{"count":6,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/pages\/21277\/revisions"}],"predecessor-version":[{"id":84549,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/pages\/21277\/revisions\/84549"}],"wp:attachment":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/media?parent=21277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/categories?post=21277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tags?post=21277"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_audience?post=21277"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_birn_id?post=21277"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_branding?post=21277"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_businessunit?post=21277"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_campaign?post=21277"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=21277"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=21277"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=21277"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_experience?post=21277"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_indication?post=21277"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_material_intent?post=21277"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_product?post=21277"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_region?post=21277"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=21277"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-therapeutic-area?post=21277"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-product?post=21277"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-pathology?post=21277"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-content-type?post=21277"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-active-ingredient?post=21277"},{"taxonomy":"mhh-area-of-interest","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/mhh-area-of-interest?post=21277"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/access?post=21277"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/user_status?post=21277"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/user_role?post=21277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}